Conditions: Acute Myeloid Leukemia
Keywords: Acute myeloid leukemia Relapsed or refractory acute myeloid leukemia Children Decitabine DACOGEN Cytarabine
Allocation:  | Intervention model: SEQUENTIAL
Enrollment: 17
Healthy volunteers: no

Brief summary:
The purpose of this study is to examine the safety and efficacy of decitabine in sequential administration with cytarabine in children with relapsed or refractory acute myeloid leukemia (AML).

Detailed description:
This is an open-label (identity of assigned study drug will be known) study to evaluate safety, efficacy, and pharmacokinetics (study of what the body does to a drug) of decitabine in sequential administration with cytarabine in children with relapsed or refractory AML. The study will determine the maximum tolerated dose of cytarabine that can be given following decitabine (Phase 1) and the response rate to this combination (Phase 2). Participants may enter a continuation phase of single agent-decitabine infusions for as long as such treatment would be considered beneficial. Serial pharmacokinetic samples will be collected and safety and efficacy will be monitored throughout the study.

Arms:
arm 1: None

Interventions: intervention 1: Phase1 and Phase 2: decitabine intervention 2: Phase 1: cytarabine intervention 3: Phase 2: cytarabine
Intervention descriptions: intervention 1: 20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle) intervention 2: 1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose intervention 3: Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)

Protocol document:
Prot_SAP_000.pdf: 
1
Approved, Date: 6 October 2015  
Janssen Research & Development *
Clinical Protocol
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With 
Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Protocol DACOGENAML2004; Phase 1-2
AMENDMENT INT-2
JNJ-30979754 (decitabine)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact Information 
page that accompanies the protocol.
EudraCT NUMBER: 2013-000390-70
Status:
Approved
Date:
6 October 2015
Prepared by:
Janssen Research & Development, LLC 
EDMS Number:
EDMS-ERI-57650672:3.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or 
confidential.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
2
Approved, Date: 6 October 2015  
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 4
PROTOCOL AMENDMENTS....................................................................................................................... 5
SYNOPSIS.................................................................................................................................................... 9
TIME AND EVENTS SCHEDULE .............................................................................................................. 13
ABBREVIATIONS ...................................................................................................................................... 16
1.
INTRODUCTION................................................................................................................................ 17
1.1.
Background .................................................................................................................................... 17
1.1.1.
Childhood Acute Myeloid Leukemia ........................................................................................... 17
1.1.2.
Rationale for DACOGEN Treatment of Patients with AML......................................................... 18
1.1.3.
Nonclinical Studies Relevant to This Protocol............................................................................ 19
1.1.3.1.
Preclinical Studies of Pediatric AML Explants......................................................................... 19
1.1.3.2.
Sensitivity and Resistance of Combinations of Decitabine and Cytarabine............................ 20
1.1.3.3.
Rat Juvenile Toxicology........................................................................................................... 20
1.1.4.
Clinical Studies ........................................................................................................................... 21
1.1.4.1.
Human Pharmacokinetic Studies ............................................................................................ 22
1.1.4.2.
Efficacy/Safety Studies............................................................................................................ 23
1.1.4.2.1.
Efficacy of DACOGEN in Adult Subjects with Acute Myeloid Leukemia ............................. 23
1.1.4.2.2.
Safety of DACOGEN in Adult Subjects with Acute Myeloid Leukemia................................ 24
1.2.
Combination Therapy..................................................................................................................... 24
1.3.
Overall Rationale for the Study...................................................................................................... 25
2.
OBJECTIVES AND HYPOTHESES.................................................................................................. 26
2.1.
Objectives ...................................................................................................................................... 26
2.2.
Hypotheses .................................................................................................................................... 26
3.
STUDY DESIGN AND RATIONALE ................................................................................................. 27
3.1.
Overview of Study Design.............................................................................................................. 27
3.1.1.
Phase 1 Portion of DACOGENAML2004 ................................................................................... 27
3.1.2.
Phase 2 Portion of DACOGENAML2004 ................................................................................... 28
3.1.3.
Continuation Phase of Study DACOGENAML2004 ................................................................... 29
3.1.4.
Follow-Up Phase of Study DACOGENAML2004 ....................................................................... 29
3.2.
Study Design Rationale.................................................................................................................. 30
4.
SUBJECT POPULATION.................................................................................................................. 32
4.1.
Inclusion Criteria ............................................................................................................................ 32
4.2.
Exclusion Criteria ........................................................................................................................... 34
4.3.
Prohibitions and Restrictions ......................................................................................................... 35
5.
TREATMENT ALLOCATION ............................................................................................................ 35
6.
DOSAGE AND ADMINISTRATION .................................................................................................. 36
6.1.
Materials and Supplies................................................................................................................... 36
6.1.1.
DACOGEN.................................................................................................................................. 36
6.1.2.
Cytarabine .................................................................................................................................. 36
6.2.
Drug Inventory and Dispensing...................................................................................................... 36
6.3.
Dosage and Administration............................................................................................................ 37
6.3.1.
Dose Delays ............................................................................................................................... 39
7.
TREATMENT COMPLIANCE............................................................................................................ 39
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
3
Approved, Date: 6 October 2015  
8.
PRESTUDY AND CONCOMITANT THERAPY ................................................................................ 39
9.
STUDY EVALUATIONS .................................................................................................................... 40
9.1.
Study Procedures........................................................................................................................... 40
9.1.1.
Overview..................................................................................................................................... 40
9.1.2.
Screening Phase ........................................................................................................................ 41
9.1.3.
Sequential Treatment Phase ...................................................................................................... 41
9.1.4.
End of Sequential Treatment Visit .............................................................................................. 42
9.1.5.
Continuation Phase .................................................................................................................... 42
9.1.6.
End of Treatment Visit ................................................................................................................ 42
9.1.7.
Follow-up Phase......................................................................................................................... 42
9.2.
Efficacy........................................................................................................................................... 43
9.2.1.
Evaluations ................................................................................................................................. 43
9.2.2.
Endpoints.................................................................................................................................... 45
9.2.3.
Pharmacokinetics Evaluations.................................................................................................... 46
9.2.4.
Analytical Procedures................................................................................................................. 46
9.2.5.
Pharmacokinetic Parameters ..................................................................................................... 47
9.3.
Pharmacokinetic/Pharmacodynamic Evaluations.......................................................................... 47
9.4.
Biomarkers ..................................................................................................................................... 48
9.4.1.
Pharmacodynamic Evaluations .................................................................................................. 48
9.4.2.
Gene Expression Profiling .......................................................................................................... 48
9.4.3.
Gene Methylation Profiling.......................................................................................................... 48
9.4.4.
Gene Mutation Profiling .............................................................................................................. 48
9.4.5.
MicroRNA Analysis ..................................................................................................................... 49
9.5.
Safety Evaluations ......................................................................................................................... 49
9.6.
Sample Collection and Handling.................................................................................................... 52
10.
SUBJECT COMPLETION/WITHDRAWAL....................................................................................... 53
10.1.
Completion ..................................................................................................................................... 53
10.2.
Discontinuation of Study Treatment (Sequential DACOGEN - cytarabine)................................... 53
10.3.
Withdrawal from the Study............................................................................................................. 54
11.
STATISTICAL METHODS................................................................................................................. 54
11.1.
Subject Information ........................................................................................................................ 54
11.2.
Sample Size Determination ........................................................................................................... 54
11.3.
Phase 1 Analysis............................................................................................................................ 55
11.4.
Efficacy Analyses ........................................................................................................................... 55
11.5.
Pharmacokinetic Analyses............................................................................................................. 56
11.6.
Pharmacokinetic/Pharmacodynamic Analyses.............................................................................. 57
11.7.
Biomarker Analyses ....................................................................................................................... 57
11.8.
Safety Analyses ............................................................................................................................. 57
11.9.
Study Evaluation Team.................................................................................................................. 59
12.
ADVERSE EVENT REPORTING ...................................................................................................... 59
12.1.
Definitions ...................................................................................................................................... 59
12.1.1.
Adverse Event Definitions and Classifications ........................................................................... 59
12.1.2.
Attribution Definitions.................................................................................................................. 60
12.1.3.
Severity Criteria .......................................................................................................................... 61
12.2.
Procedures..................................................................................................................................... 61
12.2.1.
All Adverse Events...................................................................................................................... 61
12.2.2.
Serious Adverse Events ............................................................................................................. 62
12.2.3.
Disease Progression................................................................................................................... 64
12.2.4.
Pregnancy................................................................................................................................... 64
12.3.
Contacting Sponsor Regarding Safety........................................................................................... 64
13.
PRODUCT QUALITY COMPLAINT HANDLING.............................................................................. 64
13.1.
Procedures..................................................................................................................................... 65
13.2.
Contacting Sponsor Regarding Product Quality ............................................................................ 65
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
4
Approved, Date: 6 October 2015  
14.
STUDY DRUG INFORMATION......................................................................................................... 65
14.1.
Physical Description of Study Drug(s) ........................................................................................... 65
14.2.
Packaging ...................................................................................................................................... 65
14.3.
Labeling.......................................................................................................................................... 65
14.4.
Preparation, Handling, and Storage............................................................................................... 65
14.5.
Drug Accountability ........................................................................................................................ 65
15.
STUDY-SPECIFIC MATERIALS....................................................................................................... 66
16.
ETHICAL ASPECTS ......................................................................................................................... 66
16.1.
Study-Specific Design Considerations........................................................................................... 66
16.2.
Regulatory Ethics Compliance....................................................................................................... 67
16.2.1.
Investigator Responsibilities ....................................................................................................... 67
16.2.2.
Independent Ethics Committee or Institutional Review Board ................................................... 67
16.2.3.
Informed Consent/assent............................................................................................................ 68
16.2.4.
Privacy of Personal Data ............................................................................................................ 70
16.2.5.
Country Selection ....................................................................................................................... 70
17.
ADMINISTRATIVE REQUIREMENTS .............................................................................................. 70
17.1.
Protocol Amendments.................................................................................................................... 70
17.2.
Regulatory Documentation ............................................................................................................ 71
17.2.1.
Regulatory Approval/Notification ................................................................................................ 71
17.2.2.
Required Prestudy Documentation............................................................................................. 71
17.3.
Subject Identification, Enrollment, and Screening Logs ................................................................ 72
17.4.
Source Documentation................................................................................................................... 72
17.5.
Case Report Form Completion ...................................................................................................... 73
17.6.
Data Quality Assurance/Quality Control ........................................................................................ 73
17.7.
Record Retention ........................................................................................................................... 74
17.8.
Monitoring ...................................................................................................................................... 74
17.9.
Study Completion/Termination....................................................................................................... 75
17.9.1.
Study Completion ....................................................................................................................... 75
17.9.2.
Study Termination....................................................................................................................... 75
17.10.
On-Site Audits ................................................................................................................................ 75
17.11.
Use of Information and Publication................................................................................................ 76
REFERENCES............................................................................................................................................ 78
INVESTIGATOR AGREEMENT ................................................................................................................. 81
LAST PAGE................................................................................................................................................ 81
LIST OF IN-TEXT TABLES AND FIGURES
TABLES
Table 1:
Summary of Population PK Analysis for a Typical Patient (5-Day and 3-Day Regimen)......... 22
Table 2:
Most Frequently Reported Adverse Events in the Integrated AML Studies DACO-016 
and DACO-017 ......................................................................................................................... 24
Table 3:
Dose Escalation and De-Escalation Algorithm for the “rolling 6” Design ................................. 38
Table 4:
Volume of Blood to be Collected From Each Subject............................................................... 41
Table 5:
Statistical Assessments of Response of CR + CRi (N=15) ...................................................... 56
FIGURES
Figure 1:
Chemical Structure of Decitabine ............................................................................................. 19
Figure 2:
Number of Subjects Participating in DACOGEN Clinical Studies ............................................ 21
Figure 3:
Schematic Overview of the Study............................................................................................. 29
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
5
Approved, Date: 6 October 2015  
PROTOCOL AMENDMENTS
Protocol Version
Issue Date
Original Protocol
11 Apr 2013
Amendment INT-1
18 Jun 2014
Amendment INT-2
06 Oct 2015
Amendments below are listed beginning with the most recent amendment.
Amendment INT-2 (06 Oct 2015)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The overall reason for the amendment was to correct errors noted in the 
selection criteria and typographical errors.
Applicable Section(s)
Description of Change(s)
Rationale: The inclusion/exclusion criteria were modified based on incorrect interpretation of selection criteria.
Section 4.1, Inclusion 
Criteria #6
Section 9.1.2 Screening 
Phase
#6.2: Unit for serum creatinine; listed as dg/dL but should be mg/dL in the sentence 
below:
Glomerular Filtration Rate (ml/min/1.73 m2 = k*Height(cm)/serum creatinine (mg/dL) 
where k is a proportionality constant which….
#6.2: “and” changed to “or” in the sentence below:
Cardiac function must be normal, defined as shortening fraction of 29% by 
echocardiogram, or left ventricular ejection fraction (LVEF) >58%. 
One of the 2 cardiac function parameters should meet the threshold as stated in footnote j 
in the Time and Events (T&E) Schedule.
Section 4.2 Exclusion 
Criteria
#5.1: Unit for white blood cell count listed as 40,000 cells/mL is incorrect and should be 
expressed in standard units resulting in 40 x109 cells/L
Rationale: To provide further clarification throughout the protocol, the timing of Day 28 assessments, the End of 
Sequential Treatment Visits, sample collection of cerebrospinal fluid, hematology testing was clarified, and the 
screening period in Figure 3 was corrected.
T&E Schedule, 
column title
Clarified that the Day 28 assessments (end of cycle) can be later than Day 28, but have to 
occur within 8 days prior to the start of the next cycle.
T&E Schedule
footnote b
Clarified that the End of Sequential Treatment Visit can occur within 7 days after the end 
of the last sequential treatment cycle. 
T&E Schedule
footnote r
Clarified the exception at screening for cerebrospinal fluid (CSF) collection: Samples will 
be collected from Phase 1 and Phase 2 subjects. 0.5 ml of CSF will be collected for PK 
analysis when/if CSF is obtained as part of routine medical care except at screening.
Section 9.2.1
Clarified that the hematology testing can be performed after Day 28 if the next cycle is 
delayed: Hematology including peripheral blast counts will be performed during 
screening, at Day 1, Day 5 (first cycle only), Day 8, Day 22 (first cycle only), and Day 28 
or later if the next cycle is delayed but within 8 days of the start of the next cycle.
Figure 3
The scheme box for screening period was corrected, stating “Up to Day -14”, instead of 
Day -10, for consistency with other sections.
Rationale: To align with the current protocol template or to provide further clarification within the protocol, minor 
updates were implemented as described below.
Title page
Updated sponsorship statement on the title page to replace "Janssen R&D Ireland" with 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
6
Approved, Date: 6 October 2015  
Applicable Section(s)
Description of Change(s)
"Janssen Sciences Ireland UC.
4.1 Inclusion Criteria;
4.2 Exclusion Criteria
Provided further granularity in describing the changes that were made for 
Amendment INT-1 versus the current Amendment INT-2.
Throughout the 
protocol
Minor grammatical, formatting, or spelling changes were made.
Amendment INT-1 (18 June 2014)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The overall reason for the amendment is to facilitate enrollment into the 
study and provide clarity on some aspects of the protocol.
Applicable Section(s)
Description of Change(s)
Rationale: The inclusion/exclusion criteria were modified based on feedback from investigators and to facilitate 
enrollment.
Section 4.1
#3: Provisions were added to allow subjects who relapse following bone marrow 
transplant to enter the study.
#6: The age range for adolescent children was specified (12 to 18 years of age).
Requirements for contact with the sponsor’s medical monitor were added in the event of 
elevated alanine aminotransferase (ALT) related to intrathecal treatment. Changed ALT 
upper boundary to 5 x upper limit of normal.
#9 and #10: Criteria were modified to delete all references to donation of eggs or sperm 
because the patient population would not be allowed to donate based on age, medical 
history, and prior treatments.
Section 4.2, Synopsis
#3: Criterion has been modified to exclude subjects with central nervous system disease 
category 3 (CNS3), including its specifications.
#8: Clarified to exclude subjects currently receiving treatment in an interventional 
investigational study.
Rationale: Clarifications were made to the timing of the Screening Period and the required procedures.
Synopsis; T&E 
Schedule; Section 4;
Section 9.1.2
Changed the Screening Period from Day -10 to Day -14 through Day 0.
T&E Schedule
Clarified that the Informed Consent form must be signed prior to the commencement of 
any screening procedures, but is not considered a screening procedure itself.
Rationale: To clarify cardiac assessment requirements
T&E Schedule, footnote 
“j”
Added text: Results of cardiac assessments performed more than 14 days prior to 
enrollment are acceptable provided no potentially cardiotoxic medications were 
administered between that evaluation and Cycle 1 Day 1.
Section 4.1 #6;
Section 9.1.2
Clarification of acceptable time interval for cardiac function tests prior to the study for 
screening.
Rationale: Investigational sites are being referred to the Investigational Product instruction manual for handling and 
preparation instructions for DACOGEN. This reference is now routinely included in protocols.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
7
Approved, Date: 6 October 2015  
Applicable Section(s)
Description of Change(s)
Section 6.1.1;
Section 14.4
The handling and preparation specifications for DACOGEN were removed. A reference 
was added to the Investigational Product instruction manual (or equivalent) for these 
specifications.
Rationale: Removed cytarabine based on the fact that all health authorities have accepted cytarabine as 
non-investigational medicinal product (IMP)
Section 6.1.2; Section 
6.2
References to the Sponsor’s responsibility for supply of cytarabine study drug were 
removed. 
Rationale: For very small children, dose adjustments based on weight are performed standardly at all 
investigational sites, therefore it is being specified in the protocol to ensure consistency in dosing for all study sites 
and ensure accurate dosing for very small children.
Section 6.3
For subjects <1 year old or subjects <10 kg, dosing of study drug should be based on the 
subject’s body weight rather than body surface area (BSA). This conversion is calculated 
as dose described by BSA in mg/m2 divided by 30 and multiplied by body weight (kg).
A “Dose Delays” section was given a separate subheading of Section 6.3.1.
Rationale: Clarification in prestudy and concomitant therapy was made in response to questions from sites.
Section 8
Wording for prestudy therapy was clarified. A separate paragraph was added allowing 
prophylactic intrathecal therapy and hydroxyurea until 1 day prior to Cycle 1 Day 1.
Rationale: To remove redundancy in the Overview of Study Procedures
Section 9.1.1 
Paragraph on blood sampling for biomarkers and pharmacokinetics assessments was 
removed.
Rationale: To clarify length of follow-up for assessment of long-term toxicity.
T&E schedule, footnote 
“d”; Section 3.1.4
Follow-up is to include recording of any late-occurring, potentially study drug-related 
adverse events, date(s) of any further treatment, drugs, and doses used and date of death,
and should occur every 3 months for a maximum of 3 years after the last subject is 
enrolled or until 80% of patients are deceased, whichever occurs first.
Rationale: Clarify the start of next cycle in response to questions from sites
Section 9.1.3
The next cycle of study drug can be started per investigator decision if the subject has 
recovered from acute toxicity and does not meet any of the discontinuation criteria
Rationale: Clarify the tests required for bone marrow examination
Section 9.2.1
Clarified testing required with added text as follows: “Cytogenetic evaluations will be 
performed at screening. If tests such as immunophenotyping and/or cytochemical 
evaluations have been done for standard medical care prior or within screening period, 
the data will be collected in the eCRF.”
Rationale: To ensure compliance with protocol-specified pharmacokinetics evaluations treating (very) small 
children and lessen the burden for them
Section 9.2.3;
T&E Schedule, footnote 
“r”
Pharmacokinetics (PK) samples can be taken via a central line if the decitabine infusion 
is given peripherally. If attempts to place a peripheral line are unsuccessful, and 
decitabine is given through a single lumen central line, consider to only collect 
pre-infusion and post-infusion PK samples.
Rationale: To clarify frequency of urine pregnancy testing for female subjects.
Section 9.5
Urine or serum pregnancy testing for females of childbearing potential at screening is 
required and during the study when clinically indicated
Rationale: Correction of minor errors; minor wording clarifications
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
8
Approved, Date: 6 October 2015  
Applicable Section(s)
Description of Change(s)
Throughout the protocol
Minor grammatical, formatting, or spelling changes were made. Additions were made to 
the Abbreviations list as needed. Minor wording clarifications were made throughout.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
9
Approved, Date: 6 October 2015  
SYNOPSIS
Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in 
Children With Relapsed or Refractory Acute Myeloid Leukemia
DACOGEN®, the formulated product of the active agent decitabine (5-aza-2’-deoxycytidine), is a DNA 
hypomethylating agent approved for the treatment of older patients with acute myeloid leukemia (AML). 
This protocol extends the evaluation of DACOGEN to the treatment of relapsed/ refractory pediatric 
patients with AML from 1 month to less than 18 years old. This is an open label, multicenter Phase 1-2 
study that investigates the pharmacokinetics (PK), safety, and efficacy of a sequential administration of 
DACOGEN followed by cytarabine.
OBJECTIVES AND HYPOTHESES
Primary Objectives
The primary objectives of the Phase 1 portion of Study DACOGENAML2004 are:

to determine the maximum tolerable dose (MTD) of cytarabine (up to 2 g/m2 per day x 5) that can be 
administered on Days 8-12 following treatment with DACOGEN 20 mg/m2 per day on Days 1-5 of a 
28-day cycle.

to determine decitabine PK parameters from blood sampling on Day 5 of Cycle 1. (PK parameter 
determinations are a secondary endpoint in the Phase 2 portion of the study)
The primary objective of the Phase 2 portion of Study DACOGENAML2004 is to determine the response 
rate (complete remission [CR] + complete remission with incomplete blood count recovery [CRi]) in 
children with relapsed or refractory AML when treated with DACOGEN 20 mg/m2 per day on Days 1-5 
followed by cytarabine at the determined MTD on Days 8-12 for up to 4 cycles of treatment.
Secondary Objectives
The secondary objectives are to evaluate the safety profile of DACOGEN 20 mg/m2 per day administered
on Days 1-5 followed by cytarabine Days 8-12 for up to 4 cycles of therapy, to describe the duration of 
CR + CRi, and evaluate the overall response rate (CR + CRi + partial response [PR]) to treatment.
Other objectives are: to determine the event-free survival (EFS) and overall survival (OS) for subjects 
treated with the sequential administration of DACOGEN and cytarabine, to explore the pharmacodynamic 
effects of DACOGEN with respect to DNA hypomethylation status and gene expression, and to explore 
predictive biomarkers for response to DACOGEN and cytarabine sequential treatment. The plasma PK 
profile of decitabine is a secondary endpoint in the Phase 2 portion of this study. Additionally, levels of 
decitabine in the cerebrospinal fluid (CSF) will be evaluated if samples are collected as part of other 
required medical care.
Hypotheses
The hypothesis to be tested in the Phase 1 portion of this study is that DACOGEN administered at 
20 mg/m2 per day for 5 consecutive days followed by at least 1 g/m2 per day (but not more than 2 g/m2
per day) of cytarabine on Days 8-12 can safely be given to children with relapsed or refractory AML.
The Phase 2 portion of the study is based on the hypothesis that the sequential administration of 
DACOGEN and cytarabine induces responses in pediatric patients with relapsed/refractory AML. It does 
not have formal hypothesis testing but is aimed to obtain initial efficacy and additional safety data of the 
sequential administration of DACOGEN and cytarabine.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
10
Approved, Date: 6 October 2015  
OVERVIEW OF STUDY DESIGN
For the Phase 1 portion of the study, a “rolling 6” design39 is used. The total number of participants is 
dependent upon the number of cytarabine dose levels tested; the maximum number of which is 3 dose 
levels (1 g/m2, 2 g/m2, and 1.5 g/m2) with a maximum of 18 evaluable subjects.
The Phase 2 portion of the study will be an open-label, single arm study of the sequential administration 
of DACOGEN and cytarabine in at least 15 evaluable children with relapsed or refractory AML. The 
primary endpoint for the Phase 2 portion is the CR + CRi response rate. The observed response rate of CR 
+ CRi will be descriptively evaluated compared with a clinically uninteresting level of 20% and a 
clinically interesting level of 35%.
After completing up to 4 cycles of sequential DACOGEN - cytarabine treatment in either Phase 1 or 
Phase 2 of this study, subjects who, in the opinion of the treating physician, may benefit, can receive 
single agent DACOGEN at 20 mg/m2 IV infusion over 1 hour on Days 1-5 every 28 days in the study 
Continuation Phase. Cycles can be repeated for as long as such treatment is considered beneficial.
Subjects who discontinue DACOGEN - cytarabine sequential treatment may enter the Continuation Phase
of the study if, in the opinion of the treating physician, the subject would benefit.
SUBJECT POPULATION
This study will enroll children with relapsed or refractory AML who are 1 month of age to less than 
18 years old. Screening for eligible subjects will be performed within 14 days before administration of 
any study drug.
Major inclusion criteria are:

Subject must have a histological diagnosis of AML according to the World Health Organization 
(WHO) classification

Subject must have AML which has relapsed or is refractory to standard of care and for which no 
curative therapy exists 

Subject must have a Karnofsky or Lansky score of at least 50

Subject must be recovered from acute toxicity of any prior treatment

Subject must have adequate organ function
Major exclusion criteria are:

Subject has had prior treatment with DACOGEN or azacitidine (Vidaza) 

Subject has acute promyelocytic leukemia (M3 subtype in the French-American-British [FAB] 
classification system).

Subject has central nervous system disease category 3 (CNS3)

Subject has AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, 
Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure 
associated with inherited syndromes

Subject is currently enrolled in the treatment phase of an interventional investigational study.
DOSAGE AND ADMINISTRATION
DACOGEN will be administered as a 1-hour IV infusion of 20 mg/m2 once daily for 5 consecutive days 
on Days 1 to 5 of each 28 day cycle. Cytarabine will be administered as an IV infusion over 4 hours daily 
for 5 consecutive days (Day 8 to Day 12).
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
11
Approved, Date: 6 October 2015  
The MTD of cytarabine will be determined in the Phase 1 portion of the study. The starting dose of 
cytarabine will be 1 g/m2 per day x 5 days and the second dose level will be 2 g/m2 per day x 5 days. If the 
first dose level is not tolerated the study will stop since cytarabine 1 g/m2 per day x 5 days is the lowest 
dose generally used in this setting. If the first dose level is tolerated but the second dose level exceeds the 
MTD, an intermediate dose level, 1.5 g/m2 per day x 5 days will be evaluated.
In the Phase 1 portion, dose limiting toxicity (DLT) will be assessed for each subject up to the end of 
Cycle 1 of the sequential DACOGEN - cytarabine treatment. Subjects will be enrolled into Phase 1 using 
a “rolling 6” design39 that determines the next subject’s dose level of cytarabine based upon the number of 
subjects evaluable at the current dose level, how many subjects had DLTs, and how many subjects have 
safety data pending. There will be no intra-subject dose escalation. A minimum of 2 subjects and up to 
6 subjects will be enrolled at each dose level. Each subject may receive 4 cycles of sequential treatment 
unless criteria for treatment discontinuation are reached sooner.
The Phase 2 portion of the study will be an extension of the Phase 1 portion and treat subjects with 
DACOGEN as a 1-hour IV infusion of 20 mg/m2 once daily for 5 consecutive days on Days 1 to 5 
followed by cytarabine at the MTD (determined in Phase 1) over a 4 hour IV infusion daily for 
5 consecutive days (Day 8 to Day 12). Cycles are 28 days. Four cycles of sequential treatment are to be 
administered unless criteria for treatment discontinuation are reached sooner.
The Continuation Phase of the study will treat subjects with DACOGEN as a single agent; a 1-hour IV 
infusion of 20 mg/m2 once daily on Days 1 to 5 of a 28-day cycle. 
EFFICACY EVALUATIONS/ENDPOINTS
Efficacy evaluations will be performed on Day 28 of each cycle or within 8 days of the start of the next 
cycle. Response will be assessed using International Working Group (IWG) criteria6. The best response 
from up to 4 cycles of sequential treatment for each subject in the Phase 2 portion of the study will be 
used to determine the primary endpoint, response rate of CR + CRi. To be evaluable, subjects must 
complete at least 2 cycles of the sequential treatment and have at least 1 post-baseline disease assessment
unless subjects discontinued treatment before Cycle 2 with disease progression or response (CR, CRi, or 
PR). Other efficacy endpoints include duration of response for subjects who achieve CR, CRi, overall
response rate (CR + CRi + PR), OS, and EFS.
PHARMACOKINETIC EVALUATIONS
In Phase 1 and Phase 2, serial whole blood samples (0.5mL each) for PK will be obtained on Day 5 of 
Cycle 1 for determination of decitabine plasma concentrations. Cytarabine PK parameters will not be 
assessed. In subjects whose course of routine treatment includes sampling of CSF, a portion of that 
sample may be assessed for decitabine drug levels. 
BIOMARKER EVALUATIONS 
Biomarker evaluations will include DNA methylation analyses, DNA mutational analyses, gene 
expression, and micro RNA analyses.
SAFETY EVALUATIONS
The study will include the following evaluations of safety: adverse events (AEs), clinical laboratory tests 
(including hematology panel and serum chemistry panel), vital sign measurements (including 
temperature, heart rate, and blood pressure), physical examinations, and assessment of performance 
status.
In the Phase 1 portion of the study, the MTD for cytarabine is based on the number of subjects experiencing 
a dose limiting toxicity (DLT) by the end of Cycle 1. A non-hematological DLT is defined as: any Grade 3 
toxicity that persists for >5 days or any Grade 2 toxicity that persists for >7 days and that is intolerable to the 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
12
Approved, Date: 6 October 2015  
subject. A hematological DLT is defined as Grade 4 neutropenia or thrombocytopenia due to a hypoplastic 
bone marrow at Day 42, in the absence of malignant infiltration. The nominal duration of each cycle will be 
28 days. However, patients who have not experienced bone marrow recovery at Day 28 will be followed up 
to Day 42. Failure of marrow recovery (improvement to Grade 3) by Day 42 will be considered a DLT. The 
maximum duration of Cycle 1 will therefore be 42 days.
The decision to escalate or de-escalate cytarabine dose levels and the identification of the MTD will be 
the responsibility of a Study Evaluation Team (SET) that will convene periodically based on the number 
of evaluable patients and the occurrence of DLTs. The SET consists of the sponsor’s statistician and 
clinician and other members as needed, eg, clinical pharmacologist, safety physician. The SET will also 
contain the lead investigator or designee from each country where the study is being conducted. 
STATISTICAL METHODS
The safety population comprises subjects who signed the informed consent form (ICF) and received at 
least 1 dose of any study drug. The efficacy population is the subset of the safety population consisting of 
subjects who are evaluable for disease response. Subjects who withdraw prior to the completion of 
2 cycles for reasons other than disease progression or response (CR, CRi, or partial response [PR]) and do 
not have at least 1 post-baseline disease assessment will be considered non-evaluable for response. Where
appropriate, summaries (demographic, baseline characteristics, efficacy, and safety) will be presented for 
the Phase 1 part of the data, the Phase 2 part of the data, and data of the 2 phases combined.
The Phase 1 portion of the study will enroll up to 18 evaluable subjects (if the intermediate cytarabine 
dose is used), depending on when the MTD is determined. The Phase 2 portion of this study will include 
at least 15 evaluable subjects and is aimed to provide initial efficacy and additional safety data for the 
sequential administration of DACOGEN and cytarabine.
The primary efficacy endpoint is the response rate of CR + CRi for evaluable subjects from the Phase 2 
part of the study. Statistical analyses include the percent of subjects who achieve a CR or CRi and the 
95% confidence interval. The analyses are descriptive with the aim of assisting decision making for 
further clinical development of the sequential combination therapy. The best response observed at any 
time point during the 4 cycles of study treatment will be used. The response rate for subjects from the 
Phase 1 part of the study, and from Phase 1 and Phase 2 parts combined will also be summarized.
Duration of CR + CRi, overall response rate (CR + CRi + PR), event-free survival, and overall survival 
will be summarized. These summaries are also based on data of the Phase 2 part of the study. Where 
appropriate, these summaries will be performed on data from the Phase 1 part of the study and Phase 1 
and Phase 2 parts combined.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
13
Approved, Date: 6 October 2015  
TIME AND EVENTS SCHEDULE 
Period
Screen
Sequential Treatment Cycles (up to 4)
DACOGEN 
only cycles, 
Continuation
Day
Day
-14 to 0
Day 
1
Day 
1-5
Day 
5
Day 
8
Day 
8-12
Day 
22
Day 28 or 
later but
within 8 days 
of start of 
next cycle
End of 
Sequential
Treatment
Visitb
Q28 Days
End of 
Treatment
Visitc
Follow-upd
Study Procedures
Screening/Administrative
Informed consent/assenta
X
Inclusion/exclusion criteria
X
Medical & treatment history and 
demographicse
X
Pregnancy test
X
Study Drug Administration
Registration 
X
Dispense/administer study drugf
X
X
X
Drug accountability
X
X
X
Safety Assessments
Physical examination 
and Performance Statusg,h
X
X
X
Safety assessmenti
X
X
X
X
X
X
Cardiac assessmentj
X
X
Efficacy Assessments
Bone Marrow Aspiratek
X
X
X
Xl
Response assessment by IWG criteriam
X
X
Xl
Clinical Laboratory Assessments
Hematology n, including peripheral blast
counts
X
X
Xo
X
Xo
X
X
Xp
X
Chemistry q
X
X
X
X
Cytogenetics / molecular genetic 
characterization
X
Pharmacokinetics
Pharmacokinetics o, r
X
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
14
Approved, Date: 6 October 2015  
Period
Screen
Sequential Treatment Cycles (up to 4)
DACOGEN 
only cycles, 
Continuation
Day
Day
-14 to 0
Day 
1
Day 
1-5
Day 
5
Day 
8
Day 
8-12
Day 
22
Day 28 or 
later but
within 8 days 
of start of 
next cycle
End of 
Sequential
Treatment
Visitb
Q28 Days
End of 
Treatment
Visitc
Follow-upd
Study Procedures
Biomarkers:
Whole Bloods – DNA methylation/
mutation
X
X
X
Whole Bloodt – Gene Expression, micro 
RNA Profiling
X
X
X
Ongoing Subject Review
Concomitant therapy
Adverse events
Footnotes:
a) By parent/legal guardian and/or subject as required by local regulation. Informed consent/assent needs to be in place prior to first study-specific screening 
assessment but is not considered as a screening assessment.
b) The End of Sequential Treatment Visit occurs at the end of the last sequential treatment cycle (or within 7 days thereafter). 
c) The End of Treatment Visit occurs 30 +/- 5 days after last dose of DACOGEN plus cytarabine or single agent DACOGEN as part of this study whichever is later in 
both Phase 1 and 2. 
d) Follow-up is to include recording of any late-occurring, potentially study drug-related adverse events, date(s) of any further treatment, drugs, and doses used and 
date of death, and should occur every 3 months for a maximum of 3 years after the last subject is enrolled or until 80% of patients are deceased, whichever occurs 
first. This is the assessment of long-term toxicity.
e) To include date of initial diagnosis, prior treatments, dates of prior treatments, response, and response duration
f) DACOGEN is administered on Days 1-5 at 20 mg/m2 per day and cytarabine on Days 8-12 at the protocol defined dose.
g) Complete physical during screening (including vital signs ie, temperature, blood pressure, and pulse/heart rate) and at end of treatment. Limited examination focused 
on signs and symptoms at other times. Performance status (Karnofsky or Lansky) is evaluated prior to start of each cycle.
h) Height prior to Cycle 1 and weight prior to each cycle to determine body surface area
i)
Safety assessment at each visit during treatment to include signs and symptoms of disease, adverse events, and any other changes in condition noted.
j)
Fractional shortening lower limit of normal (29%) or LVEF (>58%) by echocardiogram (preferred). Results obtained more than 14 days prior to enrollment are 
acceptable provided no potentially cardiotoxic medications were administered between that evaluation and Cycle 1 Day 1.
k) Bone marrow aspirates will be performed at the end of Cycle 1 of sequential treatment (Day 28 or within 8 days of the start of the next cycle), the end of Cycle 2 if 
the subject did not achieve a CR at the end on Cycle 1, at the end of sequential treatment, or at any time disease progression is suspected. For Phase 1, bone marrow
aspirates at end of Cycle 1 should be obtained no later than Day 42 in order to determine potential dose limiting toxicity. If available, a portion of the bone marrow 
aspirate collected at Screening and at end of the first Cycle will be used for DNA methylation/ mutation assessment, gene expression, and micro RNA analyses.
l)
Results should be recorded if a bone marrow aspirate is obtained as part of standard clinical care. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
15
Approved, Date: 6 October 2015  
m) Response assessment is performed at time at which bone marrow aspirate is obtained.
n) Hemoglobin, platelet count, white blood cell count, absolute neutrophil count (ANC), peripheral blast count
o) First cycle only
p) For the DACOGEN continuation period, hematology samples are obtained on Day 1 of each cycle prior to drug administration.
q) To include Na+, K+, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, serum uric acid
r) 0.5 mL whole blood to be obtained (blood should not be collected through the same line through which decitabine is infused, see Section 9.2.3) at; pre-infusion, 
0.5 h during infusion, end of infusion, +5 min, +0.5h, +1h, and +2h after end infusion. Samples will be collected from Phase 1 and Phase 2 subjects. 0.5 ml of 
cerebrospinal fluid (CSF) will be collected for PK analysis when/if CSF is obtained as part of routine medical care except at screening.
s) Whole blood sample (2 mL) for DNA methylation pattern and DNA mutation determination at screening, prior to drug administration on Day, 8, and at the end of 
Cycle 1. This sample may also be used for gene expression and micro RNA analysis in the event only one biomarker blood sample can be drawn.
t)
Whole blood (2.5 mL) for gene expression profiling and micro RNA analysis at screening, prior to drug administration on Day 8, and at the end of Cycle 1.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
16
Approved, Date: 6 October 2015  
ABBREVIATIONS
AE
adverse event
ALT
alanine aminotransferase
AML
acute myeloid leukemia
ANC
absolute neutrophil count
AST
aspartate aminotransferase
AUC
area under the concentration x time curve
BM
bone marrow
BMT
bone marrow transplant
BSA
body surface area
Cl
clearance
Cmax
maximum plasma concentration
CNS
central nervous system
CNS3
central nervous system disease category 3
CRF
case report form (paper or electronic as appropriate for this study)
CR
complete Response
CRi
complete Response incomplete hematological recovery
CSF
cerebrospinal fluid
CTCAE
common terminology criteria for adverse events
DLT
dose-limiting toxicity
eCRF
electronic case report form
eDC
electronic data capture
EU
European Union
EC
ethics committee
EFS
event-free survival
FAB
French-American-British 
GCP
Good Clinical Practice
IB
Investigator’s Brochure
ICF
informed consent/assent form
ICH
International Conference on Harmonization
IEC
Independent Ethics Committee
IMP
Investigational Medicinal Product
IRB
Institutional Review Board
IVRS
interactive voice response system
IWG
International Working Group
IWRS
interactive web response system
LC-MS/MS
liquid chromatography/mass spectrometry/mass spectrometry
LV
left ventricular
MDS
myelodysplastic syndromes
MedDRA
Medical Dictionary for Regulatory Activities
MTD
maximum tolerated dose
NCI-CTCAE
National Cancer Institute Common Terminology Criteria for Adverse Events
OS
overall survival
PB
peripheral blood
PD
pharmacodynamic
PIP
Pediatric Investigational Plan
PK
pharmacokinetic
PQC
Product Quality Complaint
PR
partial response
SD
stable disease
SET
Study Evaluation Team
SmPC
summary of product characteristics
tmax
time of maximum plasma concentration
UNL
upper limit of normal
WHO
World Health Organization
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
17
Approved, Date: 6 October 2015  
1.
INTRODUCTION
DACOGEN®, the formulated product of the active agent decitabine (5-aza-2’-deoxycytidine), 
was developed in the 1960’s as a cytotoxic analog of 2’-deoxycitidine. DACOGEN has been 
shown to be a DNA hypomethylating agent at doses currently used in the clinic.2,21,32
DACOGEN is approved in the US and over 35 countries for the treatment of patients with 
myelodysplastic syndrome (MDS) and in the EU and 4 other countries (at the time of writing 
this protocol) for the treatment of patients aged 65 years and above with newly diagnosed de 
novo or secondary acute myeloid leukaemia (AML), according to the World Health 
Organization (WHO) classification, who are not candidates for standard induction 
chemotherapy. More information regarding the basis of approval for the treatment of older 
adults with AML please refer to the Investigator’s Brochure.11
This protocol incorporates recommendations from the Pediatric Development Committee of 
the European Medicines Agency from an established Pediatric Investigational Plan (PIP)
initially approved on 7 April 2010 and most recently modified on 28 March 2012. As part of 
the PIP, an initial Phase 1-2 study investigates the pharmacokinetics (PK), safety, and 
efficacy of a sequential administration of DACOGEN and cytarabine. If this combination is 
found to be safe and effective, a randomized, comparative, cooperative group Phase 3 study 
will be designed. This protocol defines the initial Phase 1-2 study.
For the most comprehensive nonclinical and clinical information regarding DACOGEN, refer 
to the latest version of the IB for DACOGEN.11
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1.
Background
1.1.1.
Childhood Acute Myeloid Leukemia
Approximately 20% of childhood leukemias are of myeloid origin and represent a spectrum 
of hematopoietic malignancies.40 The majority of myeloid leukemias are acute and the 
remainder includes chronic and/or subacute myeloproliferative disorders such as chronic 
myelogenous leukemia (CML) and juvenile myelomonocytic leukemia (JMML), as well as 
myelodysplastic syndromes.
Acute myeloid leukemia (AML) is defined as a clonal disorder caused by malignant 
transformation of a bone marrow-derived, self-renewing myeloid stem cell or progenitor, 
which demonstrates a decreased rate of self-destruction as well as aberrant differentiation. 
These events lead to increased accumulation of these malignant myeloid cells in the bone 
marrow and other organs. To be called acute myeloid leukemia, the bone marrow usually 
must include greater than 20% leukemic blasts.6,45
AML in children is comparatively rare with an estimated incidence of between five and seven 
cases per million people per year, with a peak incidence occurring at approximately 2 years 
of age. Incidence reaches a low point at an age of approximately 9 years, then increases to 
nine cases per million during adolescence and remains relatively stable until age 
55 years.7,18,49 The development of AML is associated with a variety of predisposition 
syndromes that result from chromosomal imbalances or instabilities, defects in DNA repair, 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
18
Approved, Date: 6 October 2015  
altered cytokine receptor or signal transduction pathway activation, as well as altered protein 
synthesis.28,50
There is a high concordance rate of AML in identical twins, which is believed to be in large 
part a result of shared circulation and the inability of one twin to reject leukemic cells from 
the other twin during fetal development.19 There is an estimated twofold to fourfold risk of 
fraternal twins both developing leukemia up to about age 6 years, after which the risk is not 
significantly greater than that of the general population.17,25
For AML, the 5-year survival rate for children younger than 15 years increased from less than 
20% during the period from 1975 to 1978 to 58% during the period from 1999 to 2002. For 
older adolescents (age 15-19 years), outcome was similar to that of younger children from 
1975 to 1978 but has remained lower at 35% to 40% since the late 1980s.41 There remains a 
significant proportion of patients who relapse early or fail to respond to initial treatment and 
require reinduction therapy with the ultimate aim of achieving a complete response that 
would enable stem cell transplantation to occur. The prognosis for a child with recurrent or 
progressive AML is generally poor. Approximately 50% to 60% of relapses occur within the 
first year following diagnosis, with most relapses occurring by 4 years from diagnosis. The 
vast majority of relapses occur in the bone marrow, with central nervous system (CNS) 
relapse being very uncommon.47 The length of the first remission is an important predictor of 
the potential to attain a subsequent remission. Children with a first remission of less than 1 
year have substantially lower rates of second remission compared to children whose first 
remission is greater than 1 year (approximately 50%–60% versus 70%–90%, respectively). 
Survival for children with shorter duration of first remission is also substantially lower 
(approximately 10%) compared to children for whom first remission exceeds 1 year 
(approximately 40%).43,46,48
Current treatment options for relapsed or refractory AML are limited, a number of agents are 
used as reinduction therapy an attempt to induce second remission and facilitate allogeneic 
stem cell transplant and include cytarabine, fludarabine and anthracycline based approaches.
Guidelines suggest that often the preferred option is to enter patients into clinical studies. The 
use of some form of intrathecal chemotherapy as CNS-directed treatment is considered a 
standard part of the treatment for AML, irrespective of CNS involvement.
1.1.2.
Rationale for DACOGEN Treatment of Patients with AML
Decitabine, the active substance in the formulated product DACOGEN, is a 2’-deoxycytidine 
nucleoside analog in which the #5 carbon of the nucleoside base has been modified to 
nitrogen. The generic name is decitabine or 5-aza-2’-deoxycytidine. The trade name is 
DACOGEN for Injection. The chemical structure is shown in Figure 1.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
19
Approved, Date: 6 October 2015  
Figure 1:
Chemical Structure of Decitabine 
The mechanism of action of decitabine is hypomethylation of DNA by irreversible inhibition 
of DNA methyltransferases. This inhibition leads to lower levels of methylated cytosine 
residues, a normally occurring epigenetic modification that transcriptionally silences gene 
expression. Treatment with decitabine leads to the re-expression of tumor suppressor gene 
products leading to cell differentiation, apoptosis, and senescence. Further details regarding 
the mechanism of action are provided in the IB.11
1.1.3.
Nonclinical Studies Relevant to This Protocol
1.1.3.1.
Preclinical Studies of Pediatric AML Explants
Studies have been conducted to characterize the effects of decitabine on the growth and 
cellular physiology of primary cultures of pediatric AML cell samples both in in vitro
systems and in xenograft in vivo models. These studies examined decitabine alone and in 
combination with a standard chemotherapy agent for AML, cytarabine. Additionally, these 
cellular systems were used to measure pharmacodynamic effects (DNA hypomethylation) 
and investigate potential biomarkers for decitabine activity.
Decitabine alone and combinations of decitabine plus cytarabine produced antiproliferative 
effects in primary cultures of pediatric AML cells. Generally, the potency of cytarabine was 
greater than the potency of decitabine. Concurrent administration of decitabine and 
cytarabine did not appear to alter the antiproliferative potency of cytarabine, suggesting the 
2 compounds, both cytosine analogs and utilizing similar activation pathways, do not interact.
Although the cell cycle effects were somewhat variable across the individual primary 
pediatric AML cell cultures, the most consistent finding was an increase in apoptosis 
produced by combinations of decitabine and cytarabine as determined by flow cytometry 
analysis.29
In assessments of DNA methylation, a maximal inhibition of DNA methylation was observed 
at a concentration of 50 nM decitabine after 5 days of treatment. Gene expression profiling 
was examined in 5 patient samples. Each decitabine-treated sample (50 nM for 4 days) was 
compared to the corresponding PBS vehicle treated control. The only gene expression change 
exhibiting concordant changes in expression was BCL-2, which demonstrated increased 
expression post-treatment. The relevancy of this observation is unclear because the 
observation could reflect a selection of clones with higher levels of the anti-apoptotic protein 
BCL-2 that were resistant to the apoptotic effects of decitabine in vitro. Other changes in 
gene expression were variable across the 5 patient cell samples.29
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
20
Approved, Date: 6 October 2015  
Three pediatric AML samples that were evaluated in vitro could be propagated in 
immunocompromised mice allowing for the in vivo study of therapeutic agents. Decitabine 
and cytarabine were evaluated as a daily intraperitoneal administration for 5 days as single 
agents, simultaneous administration, or sequential administration. Single agent decitabine and 
cytarabine reduced tumor burden; simultaneous treatment with decitabine plus cytarabine had 
a greater anti-leukemic effect but was associated with increased host toxicity. Sequential 
treatment with decitabine and cytarabine showed increased effectiveness compared to single 
agent administration however, without increased toxicity. There was no obvious advantage of 
the sequence of administration of the agents (decitabine followed by cytarabine versus 
cytarabine followed by decitabine). These results provide nonclinical evidence favoring 
sequential administration of decitabine and cytarabine over simultaneous administration.
Gene expression profiling was explored in the xenograft tumor samples to identify potential 
markers of treatment response but no clear biomarker for response was identified.30
1.1.3.2.
Sensitivity and Resistance of Combinations of Decitabine and 
Cytarabine
These experiments focused on determining whether combinations of decitabine and 
cytarabine led to reduced levels of decitabine triphosphate (the active decitabine moiety that 
is incorporated into DNA) and reduced antiproliferative effects of either agent based upon the 
shared intracellular pathways for metabolic activation and incorporation into DNA. HL-60 
human promyelocytic leukemia cells were selected for study based on pilot studies pertaining 
to the detection of decitabine triphosphate. Concurrent administration of cytarabine 
(IC50 concentration, 52nM) with decitabine did not affect intracellular decitabine triphosphate 
levels. Pretreatment with cytarabine for 72 hours prior to incubation with decitabine did not 
decrease decitabine triphosphate levels. A trend towards increased decitabine triphosphate 
was observed.3 Additionally, pretreatment with cytarabine for 72 hours prior to decitabine led 
to a moderate decrease in global methylation.13
Cell growth studies revealed that concomitant treatment with cytarabine and decitabine did 
not alter the relative antiproliferative potency (IC50) of either compound. Pretreatment with 
cytarabine for 72 hours prior to decitabine treatment did not alter the relative potency of 
decitabine. Pretreatment with decitabine for 72 hours prior to treatment with cytarabine 
produced an antiproliferative effect that carried over to the cytarabine incubation despite a
72 hour washout period. However, a concentration-related inhibition of cell proliferation was 
still observed with the addition of cytarabine and the relative potency did not appear to be 
altered.14
In conclusion, studies in the HL-60 promyelocytic leukemia cell line indicated that 
pretreatment with decitabine or cytarabine did not reduce the effectiveness of subsequent 
treatment of HL-60 cells with the agents under study. 
1.1.3.3.
Rat Juvenile Toxicology
In the neonatal/juvenile rat, subcutaneous/IV (bolus) dosing of decitabine starting on Day 7 
or 11 of age and lasting until Day 35 of age,12 resulted in dose related inhibition of blood cell 
formation in the bone marrow and histopathological changes in the lymphoid tissue and bone 
marrow. At the end of the recovery period until at least Day 70 of age, minimal 
focal/multifocal seminiferous tubular atrophy/degeneration was recorded in the testes in the 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
21
Approved, Date: 6 October 2015  
highest dose group (subcutaneous/IV: 5.4/1.8 mg/m2 per day [0.9/0.3 mg/kg per day]). 
Growth and the age of attainment of sexual maturity were also affected. The highest dose 
tested was the no observed effect level (NOEL) for survival, neurobehavioral development, 
and reproductive capacity.
1.1.4.
Clinical Studies
The development program for DACOGEN focused on the treatment of older patients with 
MDS and AML as well-characterized patient populations with a high unmet medical need. 
Figure 2 illustrates the studies and corresponding number of subjects evaluated in Company 
studies. In total, 1,155 subjects were entered in the clinical studies (2 studies in AML and 
4 studies in the closely-related condition, higher-risk MDS). Efficacy of DACOGEN in AML 
is evaluated in the Phase 3 study DACO-016 and the Phase 2 study DACO-017. Patients who 
had received prior therapy for AML as well as patients with favorable cytogenetics or acute 
promyelocytic leukemia were excluded from these studies. Baseline parameters of 
demographics and subject and disease characteristics were very similar between the 2 studies 
with the exception of age. Study DACO-016 enrolled subjects 65 years of age or older, 
whereas Study DACO-017 enrolled subjects 60 years of age or older. 
Figure 2:
Number of Subjects Participating in DACOGEN Clinical Studies 
Total
N=1,155
AML Studies
N=540
MDS Studies
N=615
Controlled Study
N=485
Controlled Studies
N=403
DACO-016
N=485
EORTC-06011
N=233
  DAC
    N=242
    DAC
    N=119
    cytarabine
    N=215
    SC
    N=114
    SC
    N=28
D-0007
N=170
Uncontrolled Study
N=55
    DAC
    N=89
    SC
    N=81
DACO-017
N=55
Uncontrolled Studies
N=212
DACO-020
N=99
ID03-0180a
N=93
DACO-018b
N=16
MDS-1001b
N=4
AML=acute myeloid leukemia; DAC=DACOGEN; MDS=myelodysplastic syndromes; 
SC=supportive care.
a
ID03-0180 includes only those subjects who were treated with DACOGEN 20 mg/m2
IV daily for 5 consecutive days every 4 weeks.
b
DACO-018 and MDS-1001 studies were used for pharmacokinetic determinations 
only.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
22
Approved, Date: 6 October 2015  
The AML studies demonstrated clinical improvements for older subjects treated with 
DACOGEN through an increased response rate, prolonged PFS and EFS, and a survival 
improvement over standards of care while maintaining a well-defined safety profile 
characterized predominantly by myelosuppression or consequences of myelosuppression that 
can be managed with routine supportive care.
1.1.4.1.
Human Pharmacokinetic Studies
The population PK parameters of decitabine in adults were pooled from 3 clinical studies 
(DACO-017 [n=11], DACO-020 [n=11] and DACO- 016 [n=23]) utilizing the 5-Day 
regimen (20 mg/m2 IV infusion for 1-hour x 5 days every 4 weeks) and 1 study, DACO-018 
(n=12), utilizing the 3-Day regimen (15 mg/m2 IV infusion over 3-hours every 8 hours x 
3 days every 6 weeks) in MDS or AML patients. For the 5-Day regimen, decitabine PK was 
evaluated on the fifth day of the first treatment cycle. Total dose per cycle was 100 mg/m2. 
For the 3-Day regimen, decitabine PK was evaluated after the first dose of each dosing day of 
the first treatment cycle. Total dose per cycle was 135 mg/m2.
Distribution
The PK of decitabine following intravenous administration as a 1-hour (5-Day regimen) or 
3-hour (3-Day regimen) infusion was described by a linear two-compartment model, 
characterized by rapid elimination of the drug from the central compartment and by relatively 
slow distribution from the peripheral compartment. For a typical patient (weight 70 kg/body 
surface area 1.73 m2) the decitabine PK parameters are listed in Table 1 below.
Table 1:
Summary of Population PK Analysis for a Typical Patient (5-Day and 3-Day 
Regimen)
5-Day Regimen
3-Day Regimen
Parameter
Predicted Value
95% CI
Predicted Value
95% CI
Cmax (ng/mL)
107
88.5 – 129
42.3
35.2 – 50.6
AUCcum (ng·h/mL)
580
480 – 695
1161
972 – 1390
t1/2 (min)
68.2
54.2 – 79.6
67.5
53.6 – 78.8
Vdss (L)
116
84.1 – 153
49.6
34.9 – 65.5
CL (L/h)
298
249 – 359
201
168 – 241
AUC=area under the plasma concentration-time curve; CL=total body clearance; Cmax=maximum observed 
concentration; t1/2=terminal elimination half-life; Vdss=mean volume of distribution at steady state
Source: Population PK Report34
Decitabine exhibits linear PK and following intravenous infusion, steady-state concentrations 
are reached within 0.5 hour. Based on model simulation, PK parameters were independent of 
time (ie, did not change from cycle to cycle) and no accumulation was observed with this 
dosing regimen. Plasma protein binding of decitabine is negligible (<1%). Decitabine mean 
volume of distribution at steady state (Vdss) in cancer patients is large indicating distribution 
of the drug into peripheral tissues. There was no evidence of dependencies on age, creatinine 
clearance, total bilirubin, or disease. 
Metabolism 
Intracellularly, decitabine is activated through sequential phosphorylation via phosphokinase
activities to the corresponding triphosphate, which is then incorporated into DNA by the 
DNA polymerase. Based on in vitro metabolism data and human mass balance study results, 
the cytochrome P450 system is not involved in the metabolism of decitabine. The primary 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
23
Approved, Date: 6 October 2015  
route of metabolism is likely through deamination by cytidine deaminase in the liver, kidney, 
intestinal epithelium, and blood. Results from the human mass balance study showed that 
unchanged decitabine in plasma accounted for approximately 2.4% of total radioactivity in 
plasma. The major circulating metabolites are not believed to be pharmacologically active. 
The presence of these metabolites in urine together with the high total body clearance and 
low urinary excretion of unchanged drug in the urine (~4% of the dose) indicate that 
decitabine is appreciably metabolized in vivo. In addition, in vitro data show that decitabine 
is a poor P-gp substrate.
Elimination
Mean plasma clearance following intravenous administration in cancer subjects was >200 L/h 
with moderate inter-subject variability (Coefficient of Variation [CV] is approximately 50%). 
Excretion of unchanged drug appears to play only a minor role in the elimination of 
decitabine. Results from a mass balance study with radioactive 14C-decitabine in cancer 
patients showed that 90% of the administered dose of decitabine (4% unchanged drug) is 
excreted in the urine.
Pediatric Data
Preliminary data from 10 subjects of a Phase 1-2 study in pediatric patients with AML ages 
2 to 16 years old indicated that decitabine PK parameters were consistent with known adult 
PK profiles.15
1.1.4.2.
Efficacy/Safety Studies
1.1.4.2.1.
Efficacy of DACOGEN in Adult Subjects with Acute Myeloid 
Leukemia
Study DACO-016 (CSR ref) was the largest randomized, active controlled, Phase 3 study in 
older (65 years) patients with AML conducted to date with 485 subjects enrolled. The main 
objective was to compare DACOGEN, administered at a dose of 20 mg/m2 once daily for 
5 consecutive days every 4 weeks (5-Day regimen), with Treatment Choice (TC) consisting 
of the subject’s choice (with physician’s advice) of the current standard care options of 
low-dose cytarabine (20 mg/m2 once daily for 10 consecutive days every 4 weeks) or 
supportive care.
The primary analysis showed a clinically meaningful trend for improved OS for subjects 
treated with DACOGEN although it did not reach statistical significance. Subsequent analysis 
of survival data with one year of additional data showed a stronger treatment effect for 
DACOGEN. The median overall survival (OS) remained 5.0 months in the TC arm and 
7.7 months in the DACOGEN arm with an improved hazard ratio of 0.82 (95% CI: 0.68, 
0.99), and nominal p=0.0373. Results for other endpoints showed significant improvements 
for DACOGEN-treated subjects in response rates, PFS and EFS. These results were 
consistent with those obtained in the Phase2 study, DACO-017. Further details are provided 
in the IB.11
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
24
Approved, Date: 6 October 2015  
1.1.4.2.2.
Safety of DACOGEN in Adult Subjects with Acute Myeloid 
Leukemia
DACOGEN safety was evaluated using integrated datasets from the AML studies DACO-016 
and DACO-017, 3-Day DACOGEN dosing in MDS studies D-0007 and EORTC-06011, and 
5-Day dosing in MDS studies ID03-0180 and DACO-020 (See Figure 2). A total of 
697 subjects treated with DACOGEN were evaluated for safety in clinical studies. The 
median duration of treatment with DACOGEN in subjects with AML was almost twice as 
long (4.14 months) compared with cytarabine treatment (2.35 months). Longer treatment 
duration for DACOGEN-treated subjects was a reflection of treatment benefit and 
tolerability. 
The most frequently reported adverse events (AEs) in subjects treated with DACOGEN were 
myelosuppression (neutropenia, thrombocytopenia, and anemia) and consequences of 
myelosuppression (infections, bleeding events, and fatigue) which were reported at a higher 
(up to 15%) frequency compared with cytarabine treatment in subjects with AML (Table 2).
Table 2:
Most Frequently Reported Adverse Events in the Integrated AML Studies
DACO-016 and DACO-017
Preferred Term
Supportive Care
Cytarabine
DACOGEN
Pyrexia
21%
39%
48%
Thrombocytopenia
14%
40%
41%
Anaemia
14%
34%
38%
Nausea
17%
31%
33%
Febrile neutropenia
0%
26%
34%
Diarrhoea
17%
24%
31%
Neutropenia
3%
23%
32%
Note: Percentages were calculated with the number of subjects in each group as the denominator. 
Note: Incidence was based on the number of subjects experiencing at least 1 adverse event, not the number of events. 
Source: Summary of Clinical safety\Table18
The longer treatment duration led to a longer reporting period for adverse events for 
DACOGEN-treated subjects compared to cytarabine-treated subjects, and this should be 
considered in safety comparisons between these groups. In the supportive MDS studies, the 
median treatment duration was 7.34 months for the 5-Day studies and 5.65 months for the 
3-Day studies. In all the DACOGEN treatment groups there were similar median dose 
intensities: in AML studies, 23.7 mg/m2 per week, in MDS 5-Day studies, 21.2 mg/m2 per 
week, and in MDS 3-Day studies, 21.1 mg/m2 per week.
No new safety signals were identified in the AML studies compared with previous experience 
with DACOGEN in patients with MDS either in clinical studies or postmarketing experience.
Further details of the safety of DACOGEN are provided in the IB.11
1.2.
Combination Therapy
Cytarabine
Study DACOGENAML2004 investigates the sequential administration of DACOGEN 
treatment followed by cytarabine. Cytarabine is indicated as an induction chemotherapy 
regimen for patients with AML and several other leukemias and lymphomas as a single agent 
or in combination with other antineoplastic agents. Cytarabine is a potent bone marrow 
suppressing agent resulting in hematological toxicities of cytopenias and anemia. Other 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
25
Approved, Date: 6 October 2015  
toxicities include gastrointestinal effects (nausea, vomiting, diarrhea, and anorexia), fever, 
alopecia, and neurotoxicity. For further information regarding cytarabine refer to the
Summary of Product Characteristics (SmPC; http://www.medicines.org.uk/EMC), or the 
SmPC for cytarabine applicable to the local country.
Cytarabine is one of the most common agents used to treat AML and other hematological 
malignancies. Combinations of cytarabine are often used with other chemotherapeutic agents 
such as anthracyclines and results in response rates in the pediatric AML population of 
between 17% and 69%.16,24 Treatment of patients with AML after first or later relapse is 
confounded by the accumulating toxicity of certain chemotherapeutic agents such as the 
anthracyclines. Other combination therapies are needed to address this unmet need. The 
preclinical experiments described in Section 1.1.1 suggest that the sequential administration 
of DACOGEN and cytarabine may provide antileukemic activity in pediatric patients, hence 
cytarabine was chosen as the agent to be combined with DACOGEN for this study.
1.3.
Overall Rationale for the Study
A significant proportion of pediatric AML patients relapses early or fails to respond to initial 
treatment. They require reinduction therapy with the ultimate aim of achieving a CR that 
would enable stem cell transplantation. The prognosis for a child with recurrent or 
progressive AML is generally poor. Approximately 50% to 60% of relapses occur within the 
first year following diagnosis, with most relapses occurring by 4 years from diagnosis.47
Clinical and preclinical data suggest that sequential dosing of DACOGEN and cytarabine
might be more effective than either agent used alone in refractory/relapsed pediatric AML. 
Preclinical data using human pediatric primary xenografts suggest the sequence of 
DACOGEN followed by cytarabine would be effective in patients with relapsed or refractory 
disease.30 Additionally, a Phase 1 study of epigenetic priming prior to treatment with standard 
“7 + 3” induction therapy showed that 20 mg/m2 of DACOGEN could safely be given for 
5 days prior to cytarabine (100 mg/2 per day x 7 days) and daunorubicin (60 mg/m2 per day x 
2 days).35
Despite commonality between the diagnosis and treatment of AML for children and adults 
there are significant differences between the diagnosis and treatment of children and adults. 
One of the principle challenges in investigating new approaches to treating pediatric patients 
is that they represent a very broad spectrum, from infants through to near adults. While in 
principle the treatment of younger children for example is no different to that of older 
individuals, the immaturity of organs in infants for example can confer a certain susceptibility 
to toxicity due to the differing pharmacokinetic and pharmacodynamic properties of certain 
drugs. In the case of cytarabine there is evidence to suggest that children younger than 
2 years old may exhibit reduced cytarabine clearance.31
The rational for this study is to examine the safety and efficacy of DACOGEN in sequential 
administration with cytarabine, which is the backbone of current standard combination 
treatments for relapsed/refractory pediatric AML. It is therefore necessary to first identify the 
dose of cytarabine that can be safely administered following DACOGEN treatment.
If the sequential combination can be safely administered with a clinically interesting level of 
activity, this would provide the basis for further evaluation in this indication.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
26
Approved, Date: 6 October 2015  
2.
OBJECTIVES AND HYPOTHESES
2.1.
Objectives
Primary Objectives
The primary objectives of the Phase 1 portion of Study DACOGENAML2004 are:

to determine the maximum tolerable dose (MTD) of cytarabine (up to 2 g/m2 per day x 5) 
that can be administered on Days 8-12 following treatment with DACOGEN 20 mg/m2 per 
day on Days 1-5 of a 28-day cycle.

to determine PK parameters including maximum plasma concentration (Cmax), Area 
under the concentration x time curve (AUC), time to maximum plasma concentration 
(tmax), and clearance (Cl) of decitabine on Day 5 of Cycle 1.
The primary objective of the Phase 2 portion of Study DACOGENAML2004 is to determine 
the response rate (CR + CRi) in children with relapsed or refractory AML when treated with 
DACOGEN 20 mg/m2 per day on Days 1-5 followed by cytarabine at the determined MTD 
on Days 8-12 for up to 4 cycles of treatment.
Secondary Objectives
The secondary objectives are to evaluate the safety profile of DACOGEN 20 mg/m2 per day
administered on Days 1 to 5 followed by cytarabine on Days 8 to 12 for up to 4 cycles of 
therapy and to describe the duration of CR + CRi and evaluate the overall response (CR + 
CRi + PR) to treatment
Other objectives are to determine event-free survival (EFS) and overall survival (OS) for 
subjects treated with the sequential administration of DACOGEN and cytarabine, to explore
the pharmacodynamic effects of DACOGEN with respect to DNA hypomethylation status
and gene expression, and to explore predictive biomarkers for response to DACOGEN and 
cytarabine sequential treatment. The plasma PK profile of decitabine is a secondary endpoint
in the Phase 2 portion of the study and levels of decitabine in the cerebrospinal fluid (CSF) 
will be evaluated if samples are collected as part of other required medical care.
2.2.
Hypotheses
The hypothesis to be tested in the Phase 1 portion of this study is that DACOGEN 
administered at 20 mg/m2 per day for 5 consecutive days followed by at least 1 g/m2 per day
(but not more than 2 g/m2 per day) of cytarabine on Days 8 to 12 can safely be given to 
children with relapsed or refractory AML.
The Phase 2 portion of the study is based on the hypothesis that the sequential administration 
of DACOGEN and cytarabine induces responses in pediatric patients with relapsed/refractory 
AML. It does not have formal hypothesis testing but is aimed to obtain initial efficacy and 
additional safety data of the sequential administration of DACOGEN and cytarabine.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
27
Approved, Date: 6 October 2015  
3.
STUDY DESIGN AND RATIONALE
3.1.
Overview of Study Design
This is an open-label, multicenter Phase 1-2 study to evaluate safety, PK, and clinical activity 
of DACOGEN in sequential administration with cytarabine in children ages 1 month to less 
than 18 years with relapsed or refractory AML. The study will determine the MTD of 
cytarabine that can be given on Days 8 to 12 following DACOGEN 20 mg/m2 per day on 
Days 1 to 5 (Phase 1) and the response rate to this combination (Phase 2). Pharmacokinetic 
sampling will occur, at predetermined timepoints on Day 5 of Cycle 1 in the Phase 1 and the 
Phase 2 portion of the study. 
3.1.1.
Phase 1 Portion of DACOGENAML2004
For the Phase 1 portion of the study, a “rolling 6” design39 is used. The total number of 
participants is dependent upon the number of cytarabine dose levels tested; the maximum 
number of which is 3 dose levels (1 g/m2, 2 g/m2, and 1.5 g/m2) with a maximum of 
18 evaluable subjects.
The MTD for cytarabine is based on the number of subjects experiencing a DLT by the end 
of Cycle 1. A non-hematological DLT is defined as: any Grade 3 toxicity that persists for 
>5 days or any Grade 2 toxicity that persists for >7 days and that is intolerable to the subject.
A hematological DLT is defined as Grade 4 neutropenia or thrombocytopenia due to a 
hypoplastic bone marrow at Day 42, in the absence of malignant infiltration. The nominal 
duration of each cycle will be 28 days. However, patients who have not experienced bone
marrow recovery at Day 28 will be followed up to Day 42. Failure of marrow recovery
(improvement to Grade 3) by Day 42 will be considered a DLT. The maximum duration of 
Cycle 1 will therefore be 42 days.
The decision to dose escalate from the starting dose of 1 g/m2 will be based on the number of 
subjects evaluable and the number pending evaluation during the first cycle. No dose 
escalation will occur unless a minimum of 3 subjects are fully evaluable with no dose 
limiting toxicity. If any additional subjects have been treated at that dose level, they must 
become evaluable before the dose can be escalated. The only exception is the setting in which 
5 patients are evaluable, no DLT has been observed and data for one subject is incomplete 
making it impossible for the MTD to be exceeded. Further details of the “rolling-6” design 
and the determination of the MTD are provided in Section 6.3.
The decision to escalate or de-escalate dose levels and the identification of the MTD will be 
the responsibility of a Study Evaluation Team (SET) that will convene periodically based on 
the number of evaluable patients and the occurrence of dose limiting toxicities. The SET 
consists of the sponsor’s statistician and clinician and other members as needed, eg, clinical 
pharmacologist, safety physician. The SET will also include the lead investigator or designee 
from each country where the study is being conducted. Further description of the SET and 
their responsibilities is provided in Section 11.9.
Subjects receiving any dose level of cytarabine in the Phase 1 portion of the study may
receive 4 cycles of study treatment unless the subject meets criteria for treatment 
discontinuation (Section 10.2). In adults with AML, the best response was observed after a 
median of 4 cycles of single-agent DACOGEN. Once the MTD of cytarabine is determined, 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
28
Approved, Date: 6 October 2015  
subjects treated at doses other than the MTD for less than 4 cycles can elect to proceed with 
remaining cycles at the MTD. The Phase 1 portion of the study will end when the MTD of 
cytarabine (no more than 2 g/m2 per day x 5 days) administered on Days 8-12 in sequential 
administration with DACOGEN (20 mg/m2 on Days 1-5) has been determined and all 
subjects have been treated for up to 4 cycles. Subjects who completed up to 4 cycles of the 
sequential treatment can elect to receive single-agent DACOGEN in the Continuation Phase 
of the study, if in the treating physician’s opinion it would be beneficial. In order to use 
subject data efficiently and reduce the number of subjects in the study, data from the 6 (or 
fewer) subjects who are treated at the MTD level in the Phase 1 portion may be included in 
the Phase 2 portion of the study.
3.1.2.
Phase 2 Portion of DACOGENAML2004
The Phase 2 portion of the study will be an open-label, single arm study of the sequential 
administration of DACOGEN and cytarabine in at least 15 evaluable children with relapsed 
or refractory AML. Subjects who received the MTD of cytarabine for up to 4 cycles in the 
Phase 1 portion of the study and are evaluable will be included in the evaluation of the 
Phase 2 portion of the study. Subjects may elect to receive single-agent DACOGEN in the 
continuation portion of the study if, in the opinion of the treating physician, the subject would 
benefit.
The Phase 2 portion will utilize DACOGEN 20 mg/m2 IV infusion over 1 hour on Days 1 to 
5 and the dose of cytarabine determined in Phase 1 on Days 8-12. This regimen should be 
repeated for 4 cycles of treatment unless criteria for treatment discontinuation are reached.
There will be no independent data monitoring committee.
The primary efficacy endpoint will be the response rate, ie, CR + CRi (complete remission
with incomplete blood cell count recovery) based on the evaluation up to the end of Cycle 4. 
Assessment of clinical response and disease progression will be conducted in accordance 
with the IWG response criteria.6 Bone marrow aspirates will be performed at the end of 
Cycle 1 of sequential treatment (Day 28 or within 8 days of the start of the next cycle), the 
end of Cycle 2 if the subject did not achieve a CR at the end on Cycle 1, at the end of
sequential treatment, or at any time disease progression is suspected. Safety assessments will 
include adverse event monitoring, physical examinations, clinical laboratory parameter 
(hematology and chemistry) monitoring, and assessment of performance status, as described 
in the Time and Events schedule.
The clinical cut off for the primary endpoint will occur 30 days after the last subject has 
completed sequential treatment.
Blood samples will be drawn for the assessment of pharmacokinetic parameters. Blood 
samples will also be collected for biomarker analyses to explore pharmacodynamics effects 
of DACOGEN as well as potential predictive markers for response to DACOGEN + 
Cytarabine treatment. Biomarkers planned to be analyzed include DNA methylation, gene 
expression changes, gene methylation profiling, gene mutation profiling, and micro RNA 
profiling. Blast counts and other hematological parameters will be monitored by local 
laboratories. All study evaluations will be conducted according to the Time and Events 
Schedule. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
29
Approved, Date: 6 October 2015  
3.1.3.
Continuation Phase of Study DACOGENAML2004
After completing 4 cycles of sequential DACOGEN - cytarabine treatment in either Phase 1 
or Phase 2 of this study, subjects who, in the opinion of the treating physician, may benefit,
can receive single agent DACOGEN at 20 mg/m2 IV infusion over 1 hour on Days 1-5 every 
28 days in the study Continuation Phase for as long as such treatment is considered 
beneficial. Additionally, subjects who discontinue DACOGEN - cytarabine sequential 
treatment may enter the Continuation Phase if, in the opinion of the treating physician, the 
subject would benefit. Subjects who start single agent DACOGEN will be followed for safety 
and efficacy until the treatment ends. Bone marrow aspirates will be performed only as 
clinically indicated and response assessments documented. The End of Treatment Visit 
should occur 30 days after the last dose of single agent DACOGEN after which the subjects 
will enter the Follow-up Phase of the study. In the event subjects continue to derive benefit at 
study end, DACOGEN will continue to be supplied by the Company. 
3.1.4.
Follow-Up Phase of Study DACOGENAML2004
Subjects who discontinue study treatment in the Phase 1, Phase 2, or Continuation Phase of 
the study will enter the Follow-up Phase. Follow-up assessments will occur every 3 months 
for long term safety, subsequent therapies, and survival until the end of study. The end of 
study is defined as 3 years after the last subject is enrolled or when 80% of the patients are 
deceased, whichever comes first.
A diagram of subject experience in this study is provided in Figure 3.
Figure 3:
Schematic Overview of the Study
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
30
Approved, Date: 6 October 2015  
3.2.
Study Design Rationale
Rationale for Sequential Therapy
The addition of a new agent to available regimens can mediate their clinical benefit on the 
premise that the combined agents have non-overlapping and synergistic mechanisms of 
action. 
Cytarabine is a core component of initial and later therapy for patients with AML regardless 
of patient age. AML treatment guidelines indicate that therapy should combine an 
anthracycline with standard-dose cytarabine with or without other agents, high-dose 
cytarabine alone or combined with an anthracycline, asparaginase or etoposide or using the 
purine analogues, fludarabine or 2 chloro-deoxyadenosine combined with high-dose 
cytarabine, with or without an anthracycline and/or granulocyte-colony stimulating factor.46
The recent demonstration of a role for low dose DACOGEN for the treatment of older 
patients with AML creates the opportunity to explore the potential benefit of DACOGEN in 
younger age groups.22 Limited data available from small clinical trials suggest that 
DACOGEN is active in pediatric patients with AML:

Preliminary single agent Phase 2 data in very high risk relapsed pediatric AML patients
showed that DACOGEN administered as a 20 mg/m2 IV infusion on Days 1-10
(Q 28 days) produced antileukemic effects. Of 8 subjects treated (ages 2-26, median age 
4 years) with DACOGEN, 3 subjects had a CR, complete remission with incomplete 
platelet recovery (CRp) or CRi, 3 subjects had a PR, 1 had stable disease and 1 had 
progressive disease. Median time to best response was 2.5 cycles and the drug was well 
tolerated with neutropenia as the most common toxicity with 2 serious infections in 
24 cycles.33

A Children’s Oncology Group (COG) study enrolled 2 patients with relapsed or 
refractory AML (N=2) and acute lymphocytic leukemia (ALL; N=8) between 2002 and 
2005. The starting dose of DACOGEN was 10 mg/m2 daily on Days 1-5 and 8-12 of a 
28-day cycle. The study was closed early due to poor accrual and lack of effect. 
(personal communication, Norman Lucayo, Stanford University, Stanford, CA, USA)

In an ongoing randomized pediatric study in the US and Australia the first line treatment 
of children with daunorubicin, cytarabine, and etoposide either is or is not preceded with 
a 5 day priming period with DACOGEN. Efficacy (CR + CRi) is measured 3 weeks post 
induction therapy. Initial data from 24 subjects indicates similar CR + CRi rate in both 
arms, but longer time to platelet recovery for subjects with DACOGEN priming. 
Preliminary PK data are available for 21 subjects.15
Clinical and preclinical data suggest that sequential dosing of DACOGEN and cytarabine 
might be more effective than either agent used alone in refractory/relapsed pediatric AML. A 
Phase 1 study of epigenetic priming prior to treatment with standard “7 + 3” induction 
therapy showed that DACOGEN could be given for 5 days prior to standard induction 
therapy.35 Preclinical data using human pediatric primary AML explants suggest the sequence 
of DACOGEN followed by cytarabine would be effective in patients with relapsed or 
refractory disease.30 The DACOGEN dosing regimen for this study is the same as that shown 
to be effective and approved for the treatment of adult (>65 years) patients with AML.11
Because there are no expected differences in PK parameters for decitabine between children 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
31
Approved, Date: 6 October 2015  
and adults and children typically tolerate chemotherapy better than older adults this study was 
designed to quickly identify unexpected pediatric toxicities and provide a timely assessment 
of efficacy. 
The purpose of this study is to examine the safety and efficacy of DACOGEN in sequential 
administration with cytarabine, which is the backbone of current standard combination 
treatments for relapsed/refractory pediatric AML. If the sequential treatment can be safely 
administered with a clinically interesting level of activity, then this study would provide the 
basis for further evaluation in this indication.
Phase 1:
The Phase 1 dose finding portion of the study will utilize a “rolling 6” design.39 The rolling 6 
design is a simple modification of the standard “3+3” design, and is consistent with the 
escalation rules and properties of the “3+3” design. The “rolling 6” aims to shorten the
duration of pediatric Phase 1 studies by minimizing the time the study would be closed to 
accrual for toxicity monitoring while potentially speeding the completion of study by 
eliminating the need for inter-cohort study suspension of recruitment.
This method allows accrual of 2 to 6 subjects continuously onto a dose level based on the 
numbers of subjects who are currently enrolled and evaluable, without requiring that the DLT 
status of the subjects already assigned to the same dose level is known; hence reducing the 
number of subjects who would be refused study entry due to unavailability of open slots.
Use of the “rolling 6” design is justified on the basis that pediatric trials are typically 
conducted only after completion of extensive adult trials where much of the safety 
characteristics of the drug under study are known, as is the case for DACOGEN. The use of 
this design is intended to shorten the duration of the study and enroll subjects efficiently in 
situations in which there is prior information about the dose range to be evaluated.42
Phase 2
The Phase 2 portion of this study comprises at least 15 evaluable subjects and is aimed to 
provide initial efficacy and additional safety data of the sequential administration of 
DACOGEN and cytarabine.
Biomarker Collection
Acute myeloid leukemia, in common with many haematological malignancies, is a disease 
which is defined and characterized by particular gene signatures that could be both predictive 
of response to therapy and prognostic of outcome. Further gene mutation and gene expression 
profiling research may help to explain interindividual variability in clinical outcomes and 
may help to identify population subgroups that respond differently to a drug. The goal of the 
biomarker component is to collect biological samples to allow for the identification of genetic
and other biological factors that may influence the efficacy of DACOGEN and to identify 
additional genetic and biological factors associated with AML.
Biomarker samples in the form of peripheral blood and bone marrow aspirates will also be 
collected to evaluate the mechanism of action of DACOGEN or help to explain 
interindividual variability in clinical outcomes or may help to identify population subgroups 
that respond differently to a drug. The goal of the biomarker analyses is to evaluate the 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
32
Approved, Date: 6 October 2015  
potential pharmacodynamics of DACOGEN and aid in evaluating the drug-clinical response 
relationship to decitabine + cytarabine.
Biomarker samples may be used to help address emerging issues and to enable the 
development of safer, more effective, and ultimately individualized therapies.
Biomarker analyses may be performed to assess pharmacodynamic effects across age groups
if there is an adequate distribution of subjects across age categories. Additional analyses may 
be performed to explore potential predictive markers for response to decitabine + cytarabine 
treatment.
4.
SUBJECT POPULATION
This is a Phase 1-2 pediatric study of a sequential combination of DACOGEN plus cytarabine 
in children with relapsed or refractory AML 1 month of age to less than 18 years old. 
Screening for eligible subjects will be performed within 14 days before administration of any
study drug.
The inclusion and exclusion criteria for enrolling subjects in this study are described in the 
following 2 subsections. If there is a question about the inclusion or exclusion criteria below, 
the investigator should consult with the appropriate sponsor representative before enrolling a 
subject in the study.
For a discussion of the statistical considerations of subject selection, refer to Section 11.2, 
Sample Size Determination.
4.1.
Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study.
1.
Subject must be 1 month of age to <18 years of age at the screening visit.
2.
Subject must have a histological diagnosis of AML according to the WHO 
classification
3.
Criterion modified per Amendment INT-1:
3.1. Subject must have AML which has relapsed or is refractory to standard of care 
and no curative therapy exists

Subjects in relapse must have at least 5% blasts in the bone marrow, with or 
without extramedullary disease and immunophenotypic confirmation of AML. 
Subjects who relapsed post- bone marrow transplant (BMT) are allowed, 
provided >3 months has elapsed since BMT and the subject does not have active 
graft-versus-host disease.

Subjects refractory to previous chemotherapy must have at least 20% blasts in 
the bone marrow
4.
Subject must have a Karnofsky or Lansky score of at least 50
5. 
Subject must be recovered from acute toxicity of any prior treatment
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
33
Approved, Date: 6 October 2015  
6.
Inclusion criterion has been modified:
6.1 Criterion modified per Amendment INT-1
6.2 Criterion modified per Amendment INT-2
Subject must have adequate organ function, defined as:

Normal renal function defined as a creatinine clearance of at least 
90 mL/min/1.73 m2 as determined using the Schwartz equation.37 Glomerular 
Filtration Rate (ml/min/1.73 m2 = k*Height(cm)/serum creatinine (mg/dL) 
where k is a proportionality constant which varies with age and is a function of 
urinary creatinine excretion per unit of body size; k is 0.45 for children up to 
12 months of age, 0.55 for older children and adolescent girls and 0.70 for 
adolescent boys (adolescent is referring to 12 to 18 years of age).

Alanine aminotransferase (ALT) 5 x upper limit of normal (ULN) and total
bilirubin less than 1.5 x ULN. If ALT is transiently elevated and clearly related 
to recent prophylactic intrathecal treatment since start of screening but prior to 
the first dose of decitabine, it should be discussed with the sponsor’s medical 
monitor whether the dose can be started or should be postponed.

Cardiac function must be normal, defined as shortening fraction of 29% by 
echocardiogram, or left ventricular ejection fraction (LVEF) >58%. Results 
obtained prior the screening period are acceptable provided no potentially 
cardiotoxic medication was administered between that evaluation and the first 
dose of decitabine (Cycle 1 Day 1).
7.
Any female subject of childbearing potential must practice a highly effective method 
of birth control consistent with local regulations regarding the use of birth control 
methods for subjects participating in clinical studies: eg, established use of oral, 
injected or implanted hormonal methods of contraception; placement of an 
intrauterine device (IUD) or intrauterine system (IUS); barrier methods: condom 
with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository; male partner 
sterilization (the vasectomized partner should be the sole partner for that subject); 
true abstinence (when this is in line with the preferred and usual lifestyle of the 
subject).
Note: If the childbearing potential changes after start of the study (eg, girl who is not 
heterosexually active becomes active, premenarchal girl experiences menarche) a girl
must begin a highly effective method of birth control, as described above.
8.
Female subjects of childbearing potential must have a negative serum -human 
chorionic gonadotropin (-hCG) test at screening or a negative urine pregnancy test 
at Day 1 of Cycle 1
9.
Criterion deleted per Amendment INT-1.
10.
Criterion modified per Amendment INT-1:
10.1. A male subject who is sexually active with a girl of childbearing potential and 
has not had a vasectomy must agree to use a barrier method of birth control eg, either 
condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive 
cap 
(diaphragm 
or 
cervical/vault 
caps) 
with 
spermicidal 
foam/gel/film/cream/suppository. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
34
Approved, Date: 6 October 2015  
11.
The subject and his/her legally acceptable representatives (parent(s) or guardian(s)) 
must be willing and able to adhere to the prohibitions and restrictions specified in 
this protocol.
12.
Each subject (or his/her legally acceptable representative per local regulations) must 
sign an informed consent/assent form (ICF) indicating that he or she understands the 
purpose of and procedures required for the study and are willing to participate in the 
study. Assent may be required of children capable of understanding the nature of the 
study as described in Section 16.2.3, Informed Consent/assent.
4.2.
Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from 
participating in the study.
1.
Subject has had prior treatment with DACOGEN or azacitidine (Vidaza).
2.
Subject has acute promyelocytic leukemia (M3 subtype in the French-American-
British [FAB] classification system).
3.
Criterion modified per Amendment INT-1:
3.1. Subject has central nervous system disease category 3 (CNS3), ie, more than 5 
white blood cells per microliter and positive cytospin along with clinical symptoms 
and requiring intrathecal therapy.
4.
Subject has AML associated with congenital syndromes such as Down syndrome,
Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan 
anemia, or bone marrow failure associated with inherited syndromes.
5.
Criterion has been modified per Amendment INT-2:
5.1 Subject has a white blood cell count greater than 40 x 109 cells/L
6.
Subject has known allergies, hypersensitivity, or intolerance to DACOGEN or 
cytarabine or their excipients (see Investigator's Brochure for DACOGEN details, 
SmPC for cytarabine details).
7.
Subject has contraindications to the use of cytarabine per local prescribing 
information or prior adverse reactions to cytarabine which would prevent further use.
8.
Criterion modified per Amendment INT-1:
8.1. Subject is currently enrolled in the treatment phase of an interventional 
investigational study.
9.
Subject is a female who is pregnant (positive HCG), or breast-feeding, or planning 
to become pregnant while enrolled in this study or within 3 months after the last dose 
of study drug. However, the period after which it becomes safe to become pregnant 
after the last dose of treatment is not known.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
35
Approved, Date: 6 October 2015  
10.
Subject is a male who plans to father a child while enrolled in this study or within
3 months after the last dose of study drug.
11.
Subject has any condition for which, in the opinion of the investigator, participation 
would not be in the best interest of the subject (eg, lack of recovery from surgery) or 
that could prevent, limit, or confound the protocol-specified assessments.
12.
Subject has any social or medical condition that in the investigator’s opinion renders 
the subject unfit for study participation.
13.
Subject has a history of hepatitis B surface antigen (HBsAg) or hepatitis C antibody 
(anti-HCV) positive, or other clinically active liver disease.
14.
Subject has a history of human immunodeficiency virus (HIV) antibody positive.
NOTE: Investigators should ensure that all study enrollment criteria have been met at 
screening. If a subject's status changes (including laboratory results or receipt of additional 
medical records) after screening but before the first dose of study drug is given such that they 
no longer meet all eligibility criteria, they should be excluded from participation in the study. 
Section 17.4, Source Documentation, describes the required documentation to support 
meeting the enrollment criteria.
4.3.
Prohibitions and Restrictions 
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the study to be eligible for participation:
1.
A female of childbearing potential must remain on a highly effective method of birth 
control (see inclusion criteria).
2.
A male who is sexually active with a girl of childbearing potential must use a 
double-barrier method of birth control (ie, male condom, female diaphragm or 
cervical cap, or condom) and all boys must also not donate sperm during the study 
and for 3 months after receiving the last dose of study drug.
5.
TREATMENT ALLOCATION 
Randomization and blinding is not applicable for this study. All subjects will receive 
DACOGEN and cytarabine in the Phase 1 and Phase 2 portions of the study as indicated in 
Section 6: Dosage and Administration. After completing up to 4
cycles of the 
DACOGEN - cytarabine regimen, subjects who, in the opinion of the treating physician may 
benefit, can receive single agent DACOGEN at 20 mg/m2 on Days 1 to 5 every 28 days for as 
long as such treatment is considered beneficial.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
36
Approved, Date: 6 October 2015  
6.
DOSAGE AND ADMINISTRATION
6.1.
Materials and Supplies
6.1.1.
DACOGEN
DACOGEN (decitabine) is supplied as a lyophilized powder for injection. It is supplied by 
Janssen R&D. The vials of DACOGEN must be stored according to the clinical trial label. 
For more information with regard to the chemical properties of DACOGEN, see the IB.11 For 
handling, storage, and preparation instructions, please refer to the Investigational Product 
instruction manual or equivalent.
6.1.2.
Cytarabine
Cytarabine (cytosine arabinose) is supplied commercially by the investigational site. For 
more information consult the SmPC for cytarabine for the local country.
6.2.
Drug Inventory and Dispensing
An initial supply of DACOGEN will be shipped to each site’s pharmacy when all initiation 
documents, including Institutional review Board (IRB)/ethics committee (EC) approval and 
IRB/EC-approved Informed Consent/assent, have been received and reviewed by the sponsor 
or designee and occurs upon activation of the site via the Interactive Voice Response System/ 
Interactive Web Response System (IVRS/IWRS). Cytarabine will be purchased from 
commercial sources by each study site.
Supply of DACOGEN will be managed via the IVRS/IWRS. An accurate record of shipment 
and dispensing of the DACOGEN will be maintained by the Principal Investigator or his/her 
designee. These records will be available for inspection by Janssen R&D, their 
representatives, and the regulatory authorities of applicable counties at any time. A copy of 
the DACOGEN inventory will be provided to the sponsor at the conclusion of the study or as 
the record is completed.
Drug supplies for this study are to be used only in accordance with this protocol and under 
the supervision of the Principal Investigator. The Principal Investigator must ensure that any 
unused vials of DACOGEN be returned to Janssen R&D or destroyed as authorized by 
Janssen R&D. Periodically throughout and at the conclusion of the study, vials of 
DACOGEN will be inventoried by Janssen R&D or their designee.
The investigator and pharmacist of each site will be responsible for dispensing clinical 
supplies, for exercising accepted medical and pharmacy practices, and maintaining accurate 
records of receipt of vials of DACOGEN, including date(s) received and total number of vials 
received. 
In addition, accurate records must be kept regarding when and how much of each study drug 
(DACOGEN and cytarabine) was dispensed to and used by each individual patient in the 
trial. Reasons for departure from the expected dispensing regimen must also be recorded.
Study drug inventory will be verified at each monitoring visit throughout the study. A copy of 
the study drug inventory will be provided to the sponsor at the conclusion of the study or as 
the record is completed. At the completion of the study, unopened vials of DACOGEN will 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
37
Approved, Date: 6 October 2015  
be returned to the sponsor for destruction or alternatively disposed of as authorized by the 
sponsor. 
6.3.
Dosage and Administration
DACOGEN will be administered as a 1-hour IV infusion of 20 mg/m2 once daily for 
5 consecutive days on Days 1 to 5 of each 28 day cycle. Cytarabine will be administered as 
an IV infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12). The DACOGEN
dose is considered the biologically active dose based on studies of DNA hypomethylation in 
adults and is far below (1/20th) the MTD for single-agent decitabine determined in children 
and adults.1,20 The amounts of both agents are determined by body surface area calculations. 
The dose should be recalculated if the subject’s body surface area (BSA) changes by more 
than 10%. For subjects who are less than 1 year old, or have a body weight of less than 10 kg, 
the assigned doses of DACOGEN and cytarabine should be based on the subject’s body 
weight. This conversion is calculated as dose described by BSA in mg/m2 divided by 30 and 
multiplied by body weight (kg).
The MTD of cytarabine will be determined in the Phase 1 portion of the study. The starting 
dose of cytarabine will be 1 g/m2 per day x 5 days and the second dose level will be 2 g/m2
per day x 5 days. If the first dose level is not tolerated the study will stop since cytarabine 
1 g/m2 per day x 5 days is the lowest dose generally used in this setting. If the first dose level 
is tolerated but the second dose level exceeds the MTD, an intermediate dose level, 1.5 g/m2
per day x 5 days will be evaluated.
In the Phase 1 portion, dose limiting toxicity (DLT) will be assessed for each subject who 
receives at least 1 cycle of the sequential DACOGEN - cytarabine treatment. Subjects will be 
enrolled into Phase 1 using a “rolling 6” design.39 A minimum of 2 subjects and up to 
6 subjects will be continuously enrolled at each dose level. Enrollment suspension for each 
dose level may occur only when 6 subjects have been enrolled.
Table 3 depicts the decision making algorithm for the determination of the appropriate dose 
level of cytarabine for the next enrolled subject, enrollment suspension, MTD determination, 
or study termination.
The algorithm counts only subjects who are evaluable or whose data are still pending, 
ie, subjects who are enrolled but are non-evaluable (do not complete Cycle 1 and do not 
develop DLT) are not counted. For each dose level, the algorithm starts when 2 subjects have 
been enrolled. The left portion (3 columns) of Table 3 indicates the current accrual and DLT 
status; and the right portion depicts the corresponding decisions to be made based on the 
current dose level. Since the algorithm depends on subjects’ status that can change over time,
subjects’ status as current as possible prior to the next enrollment (or other decision making)
should be obtained.
To use the algorithm, a combination of 3 key numbers should be gathered (left 3 columns of
Table 3): (1) the total number of subjects who have been enrolled at the current dose level 
minus those who are non-evaluable; (2) the number of subjects who had DLTs; and (3) the 
number of subjects who have completed Cycle 1, are evaluable, and have no DLT. The 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
38
Approved, Date: 6 October 2015  
number of subjects whose data are still pending is not essential and hence is not shown in the 
table.
For example, if 4 subjects have been enrolled at the 2.0 g/m2 per day dose level (none is 
non-evaluable), no DLT has been seen, 3 have completed Cycle 1 (this implies 1 subject with 
data pending); the 3-number combination in this case would be {4, 0, 3}. Then, shown in 
right part of the table (light gray shading), the next subject would receive the 2.0 g/m2 dose. If 
2 subjects have DLTs out of the 4 enrolled, the 3-number combination would be {4, 2, any}. 
In this case, shown in dark gray shading, the next subject would receive the 1.5 g/m2 dose 
Table 3:
Dose Escalation and De-Escalation Algorithm for the “rolling 6” Design
Number of Subjects and DLT Status
Next Enrollment Dose Level (g/m2 per day)
Subjects 
Enrolleda
Subjects
with DLT
Subjects
without DLTb
Current Dose 
level
1.0 g/m2 per day
Current Dose 
level
2.0 g/m2 per day
Current Dose 
level
1.5 g/m2 per day
2
0,1
0,1,2
1.0
2.0
1.5
2
0
Stopc
1.5
MTD=1.0
3
0,1
0,1,2
1.0
2.0
1.5
0
3
2.0
2.0
1.5
2
Any
Stopc
1.5
MTD=1.0
4
0,1
0,1,2,3
1.0
2.0
1.5
0
4
2.0
2.0
1.5
2
Any
Stopc
1.5
MTD=1.0
5
0,1
0,1,2,3,4
1.0
2.0
1.5
0
5
2.0
MTD
MTD
2
Any
Stopc
1.5
MTD=1.0
6
0,1
0,1,2,3,4
Suspend
Suspend
Suspend
0,1
5,6
2.0
MTD
MTD
2
Any
Stopc
1.5
MTD=1.0
Note: This algorithm selects 1.0 g/m2 as the MTD and stops the entire enrollment once 1.5 g/m2 exceeds the
MTD. Total number of evaluable subjects at dose level 1.0 g/m2 can be as few as 3.
a
Subjects complete Cycle 1 and evaluable for DLT, or with pending data, excluding non-evaluable subjects.
b
Subjects complete Cycle 1 and evaluable for DLT.
c
Dose level 1.0 g/m2 exceeds MTD.
Up to 18 evaluable subjects may be enrolled if the intermediate cytarabine dose level
(1.5 g/m2 per day) is tested and all 3 dose levels recruit 6 subjects.
Subjects enrolled in the Phase 2 portion of the study will receive sequential administration of 
DACOGEN and cytarabine with the MTD of cytarabine, determined in Phase 1.
For subjects enrolled in either the Phase 1 or Phase 2 portion of the study, treatment may be 
repeated for up to 4 cycles with the sequential administration of DACOGEN followed by 
cytarabine. Subjects in Phase 1 can receive up to 4 cycles at their current dose level of 
cytarabine if an MTD for cytarabine has not been established. Once an MTD for cytarabine is 
declared, subjects who are receiving cytarabine at a dose other than the MTD for less than 
4 cycles can receive the MTD dose of cytarabine for their remaining cycles as long as only 
4 cycles total are administered. Subjects may continue to be treated with DACOGEN as 
monotherapy (20 mg/m2 IV infusion over 1 hour for 5 consecuative days every 28 days) in 
the Continuation Phase as long as they are considered to derive benefit in the investigator’s 
opinion. During this period subjects will be assessed for safety, concomitant therapies, and 
adverse events and disease assessment as clinically indicated. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
39
Approved, Date: 6 October 2015  
6.3.1.
Dose Delays
Cycles may be delayed up to 28 days to allow for recovery from toxicity. Subjects with bone
marrow aplasia/hypoplasia (defined as overall marrow cellularity less than 25%) or absolute 
neutrophil count (ANC) <0.5 x 109/L or non-transfusion dependent platelet count <25 x 109/L 
should not start their next cycle until further hematopoietic recovery. The DACOGEN dose 
will be held constant but the cytarabine dose may be adjusted for toxicity.
7.
TREATMENT COMPLIANCE
Study drugs will be administered as IV infusions by qualified study-site personnel and the 
details of each administration will be recorded in the electronic Case Report Form (eCRF;
(including date, start and stop times of the IV infusion, and volume infused). Under these 
conditions treatment compliance is ensured.
8.
PRESTUDY AND CONCOMITANT THERAPY
All prior therapies for AML must be recorded. CNS-directed intrathecal therapy administered 
within 30 days before the first dose of study drugs must be recorded.
Prophylactic intrathecal therapy and hydroxyurea are allowed until 1 day prior to Cycle 1 
Day 1.
Concomitant therapies must be recorded throughout the study beginning with start of the first 
dose of study drug to 30 days after the last dose of study drug.
Concomitant therapies allowed under this protocol are: 

Packed red blood cell transfusion: transfusions may be given as clinically indicated

Platelet transfusion: to be administered when platelets are <10,000/L or according to 
institutional standards.

Prophylactic antibiotics will be administered according to institutional standards.

Management of febrile neutropenia should be in accordance with institutional standard:
Febrile neutropenia is defined as a body temperature of at least:
38.5C on 1 occasion or 38C on 2 occasions when the ANC is <1000/L. Febrile patients 
are to be evaluated by physical exam, complete blood count (CBC) with differential, and 
blood culture. Patients with febrile neutropenia or suspected sepsis on the basis of physical 
exam are to be hospitalized for appropriate broad-spectrum antibiotic coverage, consistent 
with local pathogen sensitivities.

Anti-emetics and other agents needed for supportive care may be given in accordance 
with institutional treatment standards

Any other medications required for clinical management of the patient

Other than the study agents, patients cannot receive other anticancer chemotherapy 
during this study.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies (eg, other anticancer medications) are administered.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
40
Approved, Date: 6 October 2015  
9.
STUDY EVALUATIONS
9.1.
Study Procedures
9.1.1.
Overview
The Time and Events Schedule summarizes the frequency and timing of the assessments 
applicable for this study before and during the Sequential Treatment period, the Continuation 
Phase for subjects electing to receive DACOGEN single-agent therapy, and the Follow-up 
period after the end of any study treatments.
All subjects will be followed from the first day of sequential therapy (Day 1 of Cycle 1) 
according to the assessment schedule outlined in the Time and Events Schedule regardless of 
whether the patient completes or discontinues sequential therapy (DACOGEN followed by 
cytarabine). Study assessments will be performed only after written informed consent/assent
is obtained. Every effort should be made to keep subjects on the study schedule as planned 
from Study Day 1. At each visit, study assessments should be completed before the 
administration of the study drugs. Every effort should be made to conduct disease evaluations 
as per schedule; however, post-baseline disease evaluations may be conducted 3 days from 
the scheduled visit date (based on Study Day 1), if necessary. At the following visit, the 
subject should return to the original planned schedule. Any missed visits, tests not performed, 
or examinations that are not conducted must be reported as such on the electronic case report 
form (eCRF).
Sample collections for biomarker and pharmacokinetic assessments should be kept as close to 
the specified times as possible. Other measurements may be done earlier than specified, if 
needed. Actual dates and times of the assessments must be recorded at minimum on the 
laboratory requisition forms. If required, serum or urine pregnancy tests may be performed, 
as determined necessary by the investigator or required by local regulation, to establish the 
absence of pregnancy at any time during the subject's participation in the study.
The total blood volume for the study is approximately 69 mL: 2 ml for cytogenetic 
assessment, 50 mL for safety and efficacy (including peripheral blood counts), 3.5 mL for 
PK, 6 mL for pharmacodynamic assessments, and 7.5 mL for biomarkers (Table 4).
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
41
Approved, Date: 6 October 2015  
Table 4:
Volume of Blood to be Collected From Each Subject 
Type of Samplea,b
Volume per Sample 
(mL)
No. of Samples per 
Subject
Total Volume of Blood 
(mL)c
Safety (including screening and post
treatment assessments)
- Hematology
2mL
18
36mL
- Serum chemistryd
2mL
7
14mL
Efficacy
Pharmacokinetic samples
0.5mL
7
3.5mL
Pharmacodynamic (DNA methylation/ gene 
expression)
2mL
3
6mL
Biomarkers 
2.5mL
3
7.5mL
Cytogenetics
2mL
1
2mL
Approximate Total
69mL
a
Repeat or unscheduled samples may be taken for safety reasons or technical issues with the samples.
b
Sample volumes will be adjusted according to standards for pediatric subjects
c
Calculated as number of samples multiplied by amount of blood per sample.
d
Serum chemistry includes serum -hCG pregnancy test if urine pregnancy test is not performed at the site.
Note: An indwelling intravenous cannula may be used for blood sample collection. If a mandrin (obturator) is used, blood
loss due to discard is not expected.
9.1.2.
Screening Phase
The signed ICF/assent must be obtained before any study-specific procedures are performed. 
The Screening Phase begins when the first study-specific screening assessment is conducted. 
During the Screening Phase, eligibility criteria will be reviewed and a complete clinical 
evaluation will be performed. Screening procedures will be performed up to 14 days before 
Cycle 1 Day 1; however, results of tests such as radiologic tests, bone marrow collection for 
morphology, cytogenetics, and either immunohistochemistry or immunofluorescence
performed up to 28 days before Cycle 1 Day 1 as routine work-up for the subject’s disease 
can be used. Cardiac function must be normal, defined as shortening fraction of 29% by 
echocardiogram or LVEF >58%. Results obtained prior the screening period are acceptable 
provided no potentially cardiotoxic therapy was provided between that evaluation and the 
first dose of decitabine (Cycle 1 day 1). A negative pregnancy test for females of childbearing 
potential must be documented within 7 days before the Cycle 1 Day 1 dosing. If a pregnancy 
test result is more than 7 days old at Cycle 1 Day 1, then the test must be repeated locally and 
documented. 
9.1.3.
Sequential Treatment Phase
Subjects are to receive sequential treatment in either the Phase 1 or Phase 2 portion of the 
study. Details of the procedures performed during the Treatment Phase are specified in the 
Time and Events Schedule. The Sequential Treatment Phase (DACOGEN – cytarabine)
begins on Cycle 1 Day 1 and continues until the completion of 4 cycles of treatment, 
provided there is no evidence of disease progression, unacceptable toxicity, or for the other 
reasons outlined in Section 10.2. 
Subjects will be closely monitored for adverse events, laboratory abnormalities, and clinical 
response. Clinical evaluations and laboratory studies may be repeated more frequently, if 
clinically indicated. The next cycle can be started per investigator decision as long as the 
subject has recovered from acute toxicity and does not meet any of the discontinuation 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
42
Approved, Date: 6 October 2015  
criteria (Section 10.2). If disease progression is diagnosed, then the subject will discontinue 
the study treatment, complete the End of Sequential Treatment Visit, End of Treatment Visit, 
and enter the Follow-up Phase.
9.1.4.
End of Sequential Treatment Visit
Subjects will be treated for a maximum of 4 cycles with DACOGEN - cytarabine sequential 
therapy. Once a patient completes or discontinues the sequential treatment portion of the 
study they will have the End of Sequential Treatment Visit at the end of the last cycle of 
sequential therapy.
9.1.5.
Continuation Phase 
After completing up to 4 cycles of sequential DACOGEN - cytarabine treatment or 
discontinuing sequential treatment for reasons other than progressive disease, subjects who, 
in the opinion of the treating physician are deriving benefit from DACOGEN treatment can 
continue to receive single agent DACOGEN at 20 mg/m2 IV infusion over 1 hour on 
Days 1-5 every 28 days in the study continuation phase for as long as such treatment is 
considered beneficial. Treatment may continue at the investigators discretion until the patient 
is either eligible for transplant, has progressive disease, or experiences unacceptable toxicity.
Subjects who start single agent DACOGEN will be followed for safety and efficacy until the 
treatment ends. In the event subjects continue to derive benefit at study end, DACOGEN will 
continue to be supplied by the Company. 
9.1.6.
End of Treatment Visit
Unless a subject withdraws consent from study participation, an End of Treatment Visit is to 
be scheduled 30 days 5 days after the last dose of any study drug. Every effort should be 
made to conduct the End of Treatment Visit before the subject starts any subsequent therapy. 
If a subject is unable to return to the site for the End of Treatment Visit, then the subject 
should be contacted to collect adverse events that occurred within 30 days after the last dose 
of any study drug. Additional information on reporting of adverse events can be found in 
Section 12. If the End of Sequential Treatment Visit is within 3 days of the End of Treatment
Visit Hematology and Chemistry lab assessments do not need to be repeated.
9.1.7.
Follow-up Phase 
The Follow-up Phase will begin after the completion of the End of Treatment Visit.
Follow-up assessments will be performed as specified in the Time and Events Schedule. 
Follow up visits will be performed every 3 months during the Follow-up Phase and will 
record disease progression, subsequent anticancer treatment including stem cell transplant, 
survival status, and late-occurring, potentially study-drug-related adverse events.
If the information is obtained via telephone contact, written documentation of the 
communication must be available for review in the source documents. If the subject has died, 
the date and cause of death will be collected and documented on the eCRF. Follow-up of 
subject data will continue for a maximum of 3 years from the enrollment of the last subject or 
when 80% of the patients are deceased, whichever comes first.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
43
Approved, Date: 6 October 2015  
Investigators may contact the subject to obtain follow-up information to determine the 
subject's safety or survival status (refer to Section 16.2.3, Informed Consent).
9.2.
Efficacy 
9.2.1.
Evaluations 
Efficacy evaluations will be performed according to the Time and Events Schedule until 
transplant, disease progression, withdrawal from the study, or death. Evaluations are to be 
performed ±3 days of the scheduled evaluation date (within +8 days and up to Day 42 in the 
case of end of cycle evaluations). If treatment has been delayed for any reason, then the 
disease evaluations must be performed according to appropriate point in the treatment cycle, 
resulting from changes to the dosing regimen. Response will be assessed using the IWG
criteria as published in The Journal of Clinical Oncology, 21: 4642-4642 2003 and 
erratum 22: 576, 2004.6 Response will be evaluated prior to the start of each cycle.
Hematology including peripheral blast counts will be performed during screening, at Day 1,
Day 5 (first cycle only), Day 8, Day 22 (first cycle only), and Day 28 or later if the next cycle 
is delayed but within 8 days of the start of the next cycle.
Bone Marrow Examination
Bone marrow aspirate or biopsy will be performed and examined by the local laboratory at 
screening for clinical staging (morphology is required), at the end of Cycle 1, at the end of 
Cycle 2 if the subject has not attained a CR in Cycle 1, at the End of Sequential Treatment 
Visit, and at any time disease progression is suspected. Cytogenetic evaluations will be 
performed at screening. If tests such as immunophenotyping and/or cytochemical evaluations 
have been done for standard medical care prior or within screening period, the data will be 
collected in the eCRF. During the Continuation Phase, bone marrow sampling and 
assessments will be done as clinically indicated.
For Phase 1, bone marrow aspirates at end of Cycle 1 should be obtained no later than Day 42 
in order to determine a potential DLT. 
Remission and Disease Progression/Relapse
The assessment of a response (CR or CRi), may be made only when laboratory findings meet 
specific criteria as defined by IWG.6 The timing of bone marrow assessments for efficacy 
endpoints will be driven by peripheral blast counts. Clinical judgment based on blood cell 
count recovery will dictate the exact time in each cycle when bone marrow aspirates should 
be taken.
Some patients may develop a relapse that leads to death quickly without having the 
possibility to evaluate formally the relapse of disease. Efforts should be made to obtain an 
autopsy report in such patients.
The dates of CR, CRi, PR, progressive disease, or any subsequent disease relapse after a 
response should be recorded. This should be based on the acceptable laboratory evidence 
from a bone marrow aspirate.
Details of the IWG criteria are given below:
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
44
Approved, Date: 6 October 2015  
Complete Remission 
For the following 2 CR categories, extramedullary leukemia, such as CNS or soft tissue 
involvement, must be absent. There is no stated duration of response required for a subject to 
be classified as a complete responder. 

Morphologic Complete Remission (CR) 
Per the IWG criteria, CR is defined as morphologic leukemia-free state, with less than 
5% blasts in aspirate sample with marrow spicules and with a count of 200 nucleated 
cells (there should be no blasts with Auer rods or any persistence of extramedullary 
disease), plus ANC >1,000/L platelet count of >100,000/L and subject must be 
independent of transfusions for a minimum of 1 week before each marrow assessment. 
No duration of response is required for CR. 

Morphologic Complete Remission with incomplete blood count recovery (CRi) 
Per the IWG criteria, CRi is defined as morphologic CR with residual neutropenia 
(<1,000/L) or thrombocytopenia <100,000/L). No stated duration of response is 
required for CRi. 
Partial Remission (PR) 
Per the IWG criteria, PR is defined as all the same hematologic values of a CR, but with a 
decrease of 50% of the percentage of blasts to 5% to 25% in the bone marrow aspirate. 
Therefore, if the pretreatment bone marrow blast percentage was 50% to 100%, the 
percentage of blasts must decrease to a value between 5% and 25%; if the pretreatment blast 
percentage was 20% to less than 49%, they must decrease by at least half to a value of more 
than 5%. A value of 5% blasts may also be considered a PR if Auer rods are present. There 
is no stated duration of response required for PR.
Stable Disease (SD) 
A subject who has no CR/CRi/PR nor has progressive disease for a period of at least 
2 months should be considered stable disease (SD). 
Progressive Disease 
Progressive disease is defined as: 
First Cycle: Determination of progressive disease will be based on peripheral blood (PB) 
count, evidence of new extramedullary disease and/or the clinical judgment of the 
investigator. If the blast counts in PB increases by >50% over the pre-treatment value during 
the first cycle, the subject will be considered as progressive disease if a bone marrow (BM) 
assessment was not performed. If BM assessment has been performed in first cycle or before 
the start of second cycle, then a >25% increase in the blasts count from baseline on BM 
aspirate is considered progressive disease. 
During the subsequent cycles, progressive disease will be defined as >50% increase in 
peripheral blast count from baseline, >25% increase in the blast count from baseline on BM
aspirate, or clinical evidence of new extramedullary disease or the clinical judgment of the 
investigator. Responses for patients who complete 3 or more cycles and never had a 
post-baseline bone marrow evaluation will be determined based on the clinical judgment of
the investigator.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
45
Approved, Date: 6 October 2015  
9.2.2.
Endpoints 
Primary Endpoints:
Phase 1
Dose Limiting Toxicity (DLT) for Cytarabine
For the Phase 1 portion of the study the primary endpoint will be DLT in the determination of 
the MTD (up to 2 g/m2 per day) of cytarabine given on Days 8 to 12 following the 
administration of DACOGEN at 20 mg/m2 on Days 1 to 5. DLTs are defined as the following

Hematological DLT will be defined as failure to recover to an absolute neutrophil count 
(ANC) of 0.5 x 109/L (common terminology criteria for adverse events [CTCAE]
Grade 3) and non-transfusion dependent platelet count of 25 x 109/L (CTCAE Grade 3) 
due to documented bone marrow aplasia/hypoplasia (malignant infiltration or other cause 
excluded), by Day 42. Bone marrow aplasia/hypoplasia is defined as overall marrow 
cellularity less than 25%.

Non-hematological DLT is defined as: any Grade 3 toxicity possibly, probably or 
definitely related to study drug that persists for >5 days; any Grade 2 toxicity that 
persists for >7 days and that is intolerable to the patient.
The following events are more likely disease-related and, therefore, not considered DLTs: 

Grade 3 or 4 disseminated intravascular coagulation 

Grade 3 tumor lysis syndrome; grade 3 or 4 fever or grade 3 catheter-related infection, 
febrile neutropenia, infection, infection with unknown neutrophil count, and infection 
without neutropenia 

Grade 3 or 4 hypokalemia, hypomagnesemia, hyponatremia, or hypophosphatemia that is 
related to AML or administration of antifungal medications and is corrected with IV or 
oral supplementation.
Subjects who do not complete one treatment cycle and do not develop DLT will not be 
considered evaluable for DLT.
Decitabine PK parameters including Cmax, AUC, tmax, and Cl will be determined from blood 
sampling on Day 5 of Cycle 1 and are a primary endpoint for the Phase 1 portion of the study.
Phase 2
Complete Response + Complete Response with incomplete recovery rate
In the Phase 2 portion of this study the primary end point will be the CR +CRi rate as
determined using IWG criteria. The response status of each patient will be determined prior 
to each cycle of DACOGEN + cytarabine after the first cycle. The best response up to 
4 cycles of DACOGEN + cytarabine for each subject will be used to determine the rate of CR 
+ CRi.
To be evaluable, subjects must complete at least 2 cycles of the sequential retreatment and 
have at least 1 post baseline disease assessment unless disease progression or response (CR, 
CRi, or PR) occur prior to the planned disease assessment but after Cycle 1 treatment
(ie, after Day 13 of Cycle 1).
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
46
Approved, Date: 6 October 2015  
Secondary Endpoints

Safety profile of DACOGEN 20 mg/m2 per day on Days 1-5 followed by cytarabine 
Days 8-12 for up to 4 cycles of therapy. 

Duration of CR + CRi

Overall response (CR + CRi + PR)

Event-free survival (EFS), defined as the time from first dose of study drug to relapse 
from CR, death, or second malignancy for subjects who achieve CR; subjects who do not 
achieve CR will be considered to have an event on the day of the first dose of study drug.
Other alternative EFS definitions may be considered. 

Overall survival

To determine the PK profile of DACOGEN in children with AML
Other Secondary Endpoints

To explore pharmacodynamic effects of DACOGEN with respect to DNA 
hypomethylation status and gene expression

To explore predictive markers for response to DACOGEN.

Levels of DACOGEN in the CSF if samples are collected as part of other required 
medical care.
9.2.3.
Pharmacokinetics Evaluations 
Serial whole blood samples (0.5 mL each) for PK will be obtained on Day 5 of Cycle 1 as 
indicated in the Time and Events Schedule for determination of decitabine plasma 
concentrations. Blood samples for pharmacokinetic analyses should not be collected through 
the same line through which decitabine is infused. Pharmacokinetics samples can be taken via 
a central line if the decitabine infusion is given peripherally. If attempts to place a peripheral 
line are unsuccessful, and decitabine is given through a single lumen central line, consider to 
only collect pre-infusion and post-infusion PK samples. The exact dates and times of blood 
sample collection must be recorded at minimum on the laboratory requisition forms.
In subjects whose course of routine treatment includes sampling of CSF, a portion of that 
sample may be assessed for decitabine drug levels. 
An interim PK analysis will be performed after the completion of Phase 1 PK assessments. 
Based on the results of the interim PK analysis of Phase 1, the collection timepoints of PK 
samples may be optimized and if possible reduced for the Phase 2 portion of the study. 
9.2.4.
Analytical Procedures
Pharmacokinetics
Plasma samples will be analyzed to determine concentrations of decitabine using a validated, 
specific, and sensitive liquid chromatography coupled to tandem mass spectrometry 
(LC-MS/MS) method under the supervision of the sponsor’s Bioanalytical Laboratory 
Department of Bioanalysis.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
47
Approved, Date: 6 October 2015  
PK sample collection, processing, storage, and shipping instructions for these PK blood 
samples are presented in the PK lab manual provided by the sponsor or sponsor’s 
representative.
If required, some plasma samples may be analyzed to document the presence of circulating 
metabolites using a qualified research method.
9.2.5.
Pharmacokinetic Parameters 
PK analysis will be the responsibility of the Sponsor in accordance with the sponsor’s current 
Clinical Pharmacokinetics Guideline. The following PK parameters for decitabine will be 
calculated on Day 5 of Cycle 1 by non-compartmental methods using WinNonlin Version 5.0 
or higher:
Cmax
maximum plasma concentration 
tmax
time to reach the maximum plasma concentration
AUClast
area under the plasma concentration-time curve from time 0 to the time of 
the last quantifiable concentration
AUCτ
area under the plasma concentration-time curve from time 0 to 24 hr
t1/2, 
elimination half-life associated with the terminal slope (z) of the 
semilogarithmic drug concentration-time curve, calculated as 0.693/z
z
first-order rate constant associated with the terminal portion of the curve, 
determined as the negative slope of the terminal log-linear phase of the drug 
concentration-time curve
CL
total clearance of drug after IV administration, calculated as: dose/AUCτ
VDss
volume of distribution at steady state, calculated as z /CL
Actual blood sampling times relative to study medication administration will be used for the 
analysis. Additional PK parameters may be determined as appropriate.
Cytarabine PK parameters will not be evaluated. They are already well described in this 
population at the doses planned. Since decitabine has a terminal half-life of 0.51 0.31 hour 
(DACOGEN package insert) and two full days will pass from the last dose of decitabine to 
the first of cytarabine, no drug-drug interaction is expected.
Based on the individual plasma concentration-time data, using the actual dose taken and the 
actual sampling times, pharmacokinetic parameters and exposure information of decitabine
will be derived using population pharmacokinetic modeling. Baseline covariates (eg, body 
weight, age, sex, creatinine clearance, race) may be included in the model, if relevant.
9.3.
Pharmacokinetic/Pharmacodynamic Evaluations 
Decitabine plasma concentration-time models data will also be analyzed using a population 
PK approach (non-linear mixed effect models) to establish decitabine PK parameters 
(eg, clearance and volume of distribution). The population PK model proposed for the adult 
population will be updated with the data obtained in this patient population. Data from this 
study may be combined with data from other studies to perform the population PK analysis.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
48
Approved, Date: 6 October 2015  
Analyses comparing PK parameters of Cmax and AUC with PD endpoints of DNA 
methylation and gene expression profiling may be undertaken to explore any potential 
relationships.
9.4.
Biomarkers 
Biomarker analyses are dependent upon the availability of appropriate biomarker assays and 
may be deferred or not performed if, during or at the end of the trial, it becomes clear that the 
analysis will have no scientific value or if there are not enough samples or responders to 
allow for adequate biomarker evaluation. In the event that the trial is terminated early or 
shows poor clinical efficacy, completion of biomarker assessments will be based on 
justification and intended utility of the data. Biomarker sample collections will be prioritized 
in the manner specified in Section 9.6 in the event total blood volumes exceeds the EMA 
recommendations for pediatric trial related blood loss. Biomarker samples will not be stored 
for future research.
9.4.1.
Pharmacodynamic Evaluations
DNA methylation and gene expression will be evaluated as potential pharmacodynamic 
biomarkers of the mechanism of action for DACOGEN and as response markers for 
treatment by the sequential administration of DACOGEN and cytarabine. This data will also 
be used to show biological activity across all ages enrolled in the study. Whole blood and/or 
bone marrow aspirates will be collected before study drug administration and according to 
the time and events schedule.
9.4.2.
Gene Expression Profiling
Gene expression profiling (GEP) may be evaluated in RNA for gene signatures predictive of 
response to DACOGEN. The expression of single genes such as estrogen receptor and 
p15INK4B may be examined in relation to response using RTqPCR.4 Whole blood and/or bone 
marrow aspirates will be collected before study drug administration and according to the time 
and events schedule.
9.4.3.
Gene Methylation Profiling
Gene methylation profiling will be evaluated in DNA as a predictor of response to treatment 
by the sequential administration of DACOGEN and cytarabine. The following genes will be 
highlighted for determination of efficacy: CDH1, CDH13, ER, NR4A3, NPM2, OLIG2, 
p15INK4B, PGRA, PGRB, RIL.38 Additional genes may be analyzed or global profiling may be 
applied as necessary. Whole blood and/or bone marrow aspirates will be collected before 
study drug administration and according to the time and events schedule.
9.4.4.
Gene Mutation Profiling
Gene mutations in DNMT3a and NPM127 among others plus other genetic mutations relating 
to drug response or disease, such as FLT3, IDH1, IDH2, TET2 and CEBPA, MLL-PTD, 
c-KIT, WT1, PTPN1110 will be evaluated for prediction of response to treatment by the 
sequential administration of DACOGEN and cytarabine in DNA obtained from whole blood 
and/or bone marrow aspirate. Whole blood and/or bone marrow aspirates will be collected
before study drug administration and according to the time and events schedule.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
49
Approved, Date: 6 October 2015  
9.4.5.
MicroRNA Analysis
miR29b may be evaluated for prediction of response to treatment by the sequential 
administration of DACOGEN and cytarabine in microRNA obtained from whole blood 
and/or bone marrow aspirate.5
9.5.
Safety Evaluations
The evaluation period for safety will start from the time a signed consent/assent is provided. 
Toxicity/safety will be determined using National Cancer Institute common terminology 
criteria for adverse events (NCI-CTCAE) version 4.0. 
The primary expected toxicity of cytarabine is severe myelosuppression. In addition rare 
cases of hypersensitivity and anaphylaxis have been reported after cytarabine dosing as well 
as “sudden respiratory arrest syndrome” occurring 6 to 12 hours after dosing and tumor lysis 
syndrome. 
In addition to myelosuppression, administration of DACOGEN can cause peripheral edema, 
pallor, cardiac murmur and hypotension. Fever, fatigue, headache, lethargy and other CNS 
symptoms may occur. Cough, dyspnea, pneumonia and pharyngitis may be seen as well as 
mucositis and other side effects associated with myelosuppression and cellular cytotoxicity.
For the purposes of DLT evaluation, Cycle 1 will last until the start of Cycle 2, unless there is 
no recovery from toxicity within the specified time.
During the conduct of Phase 1 the SET will evaluate the tolerability of the combination until 
such times as a MTD for cytarabine can be agreed upon. Details regarding the SET are 
provided in Section 11.9. 
During Phase 1, blood counts are to be monitored, but hematological parameters are not used to 
determine the MTD (ie, low blood counts per se are not considered to be dose-limiting toxicities
or serious adverse events) because peripheral blood counts and bone marrow function are 
compromised in patients with relapsed leukemia. Hematological toxicity will only be assessed in 
responding patients who have grade 4 neutropenia (<0.5 x109/L) or grade 4 thrombocytopenia 
(<25 x109/L) due to a hypoplastic marrow at Day 42, in the absence of leukaemia.
During Phase 2 only myelosuppression events that are considered life threatening or result in 
an admission to hospital would be considered as serious adverse events.
Safety will be measured by adverse events, laboratory test results, vital sign measurements, 
physical examination findings, and assessment of performance status. Any clinically relevant 
changes occurring during the study must be recorded on the Adverse Event section of the 
eCRF. Any clinically significant abnormalities persisting at the end of the study/early 
withdrawal will be followed by the investigator until resolution or until a clinically stable 
endpoint is reached. The study will include the following evaluations of safety and 
tolerability according to the time points provided in the Time and Events Schedule.
Any of the safety monitoring assessments may be performed more frequently, and adverse 
events should be evaluated by the investigator according to standard practice, and if clinically 
indicated.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
50
Approved, Date: 6 October 2015  
Adverse Events
Adverse events (with the exception of disease progression) will be reported by the subject 
(or, when appropriate, by a caregiver, surrogate, or the subject's legally acceptable 
representative) or by the medical staff from the time of the signed and dated ICF until 
30 days following the last dose of any study drug. Adverse events will be followed by the 
investigator as specified in Section 12, Adverse Event Reporting.
Clinical Laboratory Tests
Blood samples for serum chemistry and hematology will be collected. The investigator must 
review the laboratory report, document this review, and record any clinically relevant 
changes occurring during the study in the adverse event section of the eCRF. The laboratory 
reports must be filed with the source documents. The analysis of bone marrow samples will 
be performed locally and evaluated by the investigator.
The following tests will be performed by the local laboratory unless otherwise indicated:

Hematology Panel
-
Hemoglobin
-
platelet count
-
white blood cell (WBC) count 
-
absolute neutrophil count (ANC)
-
peripheral blast count

Serum Chemistry Panel
-
Sodium
-
Potassium
-
Creatinine
-
aspartate aminotransferase (AST)
-
alanine aminotransferase (ALT)
-
total bilirubin
-
serum uric acid

Urine or serum pregnancy testing for females of childbearing potential at screening is 
required and during the study when clinically indicated.
Vital Signs: (pulse, temperature, and blood pressure) will be performed at screening and as 
needed during the study.
Physical Examination: A complete physical examination will be performed during the 
Screening Phase. Thereafter, only a symptom directed physical examination is required. 
Abnormalities will be recorded in the appropriate section of the eCRF.
Karnofsky/Lansky Performance Status Score: Karnofsky/Lansky Performance Status 
(see) will be used to evaluate the effect of the disease status on the activities of daily living, 
and will be performed at the times specified in the Time and Events Schedule. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
51
Approved, Date: 6 October 2015  
Lansky Performance Status:26
Rating 
Description 
100 
fully active, normal 
90 
minor restrictions with strenuous physical activity 
80 
active, but gets tired more quickly 
70 
both greater restriction of, and less time spent in, active play 
60 
up and around, but minimal active play; keeps busy with quieter activities 
50 
lying around much of the day, but gets dressed; no active play; participates in all 
quiet play and activities 
40 
mostly in bed; participates in quiet activities 
30 
stuck in bed; needs help even for quiet play 
20 
often sleeping; play is entirely limited to very passive activities 
10 
does not play nor get out of bed 
0 
unresponsive 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
52
Approved, Date: 6 October 2015  
Karnofsky/ Performance Status:23,36
Condition 
Performance 
status % 
Comments 
Able to carry on normal activity and to 
work. No special care needed. 
100 
Normal. No complaints. No 
evidence of disease. 
90 
Able to carry on normal activity. 
Minor signs or symptoms of 
disease. 
80 
Normal activity with effort. Some 
signs or symptoms of disease. 
Unable to work. Able to live at home and 
care for most personal needs. A varying 
degree of assistance is needed. 
70 
Cares for self. Unable to carry on 
normal activity or to do active 
work. 
60 
Requires occasional assistance, 
but is able to care for most of 
personal needs. 
50 
Requires considerable assistance 
and frequent medical care. 
Unable to care for self. Requires equivalent 
of institutional or hospital care. Disease 
may be progressing rapidly. 
40 
Disabled. Requires special care 
and assistance. 
30 
Severely disabled. Hospital 
admission is indicated although 
death is not imminent. 
20 
Hospitalization necessary. Very 
sick, active supportive treatment 
necessary. 
10 
Moribund; fatal processes 
progressing rapidly. 
0 
Dead. 
9.6.
Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the laboratory requisition 
form. If blood samples are collected via an indwelling cannula, an appropriate amount (1 mL) 
of serosanguineous fluid slightly greater than the dead space volume of the lock will be 
removed from the cannula and discarded before each blood sample is taken. After blood 
sample collection, the cannula will be flushed with 0.9% sodium chloride, United States 
Pharmacopeia (USP) (or equivalent) or sodium heparin of 10 U/mL as per local practice and 
charged with a volume equal to the dead space volume of the lock. If a mandarin (obturator) 
is used, blood loss due to discard is not expected.
Refer to the Time and Events Schedule for the timing and frequency of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory manual that will be provided. Collection, handling, storage, and shipment of 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
53
Approved, Date: 6 October 2015  
samples must be under the specified, and where applicable, controlled temperature conditions 
as indicated in the laboratory manual.
Any volume of blood collected must be consistent the recommendations of the European 
Medicines Agency (EMA) for study related blood loss. In pediatric populations this should be 
no more than 3% of the total blood volume during a four week period and not more than 1% 
of total blood volume at a single time point. At a total blood volume estimated at 80 to 
90 mL/kg body weight this equals 2.4 to 2.7 mL of blood per kilogram of body weight every 
four weeks or 0.8 to 0.9 mL per kilogram at any one time.
It is the responsibility of the investigator to comply with these guidelines and to prioritize 
study blood collection as follows:
1. Safety laboratory studies (hematology and serum chemistry) that are trial related and not 
part of routine care
2. Pharmacokinetic samples
3. Samples for DNA methylation and DNA mutation.
4. Samples for gene expression profiling and microRNA analysis.
10.
SUBJECT COMPLETION/WITHDRAWAL
10.1.
Completion
A subject will be considered to have completed the study if he or she has completed the 
follow-up phase, has died before the end of the study, has been lost to follow up, or has 
withdrawn consent for study participation before the end of the study.
10.2.
Discontinuation of Study Treatment (Sequential DACOGEN -
cytarabine)
If a subject's study treatment must be discontinued, the End of Sequential Treatment Visit 
should be performed however, this will not result in automatic withdrawal of the subject from 
the study. The subject may, at the discretion of the investigator, receive single agent 
DACOGEN in the Continuation Phase (see Section 9.1.5), otherwise the subject will enter the 
Follow-up Phase of the study. The End of Sequential Treatment/End of Treatment Visit and 
Follow-up visit assessments should be performed as specified in the Time and Events 
Schedule.
A subject's study treatment should be discontinued if:

The subject experiences a DLT in the Phase 1 portion of the study

The investigator believes that for safety reasons (eg, adverse event) it is in the best 
interest of the subject to discontinue study treatment

The subject becomes pregnant

The subject has progressive disease by IWG criteria

The subject is non-compliant with regard to treatment visits

The subject has sufficient clinical response, in the opinion of the investigator, to be 
eligible for transplant
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
54
Approved, Date: 6 October 2015  

The subject starts another treatment regimen for AML

The subject is unable to adhere to the study visit schedule or comply with protocol 
requirements

The subject or subject’s legal representative, parent, or guardian withdraws 
consent/assent for study treatment. 
10.3.
Withdrawal from the Study
A subject will be withdrawn from the study for any of the following reasons:

Lost to follow-up

Withdrawal of consent/assent by the subject or the subject’s legal representative, parent, 
or guardian.

Sponsor terminates the study
If a subject is lost to follow-up, every reasonable effort must be made by the study site 
personnel to contact the subject and determine the reason for discontinuation/withdrawal. The 
measures taken to follow up must be documented.
When a subject withdraws before completing the study, the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study drug assigned to the withdrawn 
subject may not be assigned to another subject.
If a subject withdraws from the study the research samples will be destroyed and no further 
testing will take place. To initiate the sample destruction process, the investigator must notify 
the sponsor study site contact of withdrawal of consent/assent for the research samples and to 
request sample destruction. The sponsor study site contact will, in turn, contact the biomarker 
representative to execute sample destruction. If requested, the investigator will receive 
written confirmation from the sponsor that the samples have been destroyed.
11.
STATISTICAL METHODS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A 
general description of the statistical methods to be used to analyze the efficacy and safety 
data is outlined below. Specific details will be provided in the Statistical Analysis Plan.
11.1.
Subject Information
The safety population includes subjects who have signed the ICF and have received at least 
1 dose of any study drug. The efficacy population is the subset of the safety population 
consisting subjects who are evaluable for disease response. Where appropriate, summaries 
(demographic, baseline characteristics, efficacy, and safety) will be presented for Phase 1 part 
of the data, Phase 2 part of the data, and data of the 2 phases combined.
11.2.
Sample Size Determination
The Phase 1 portion of the study will enroll up to 12 evaluable subjects (18 if the 
intermediate cytarabine dose is used), depending on when the MTD is determined. The Phase 
2 portion of the study will enroll at least 15 evaluable subjects including those who received
the MTD of cytarabine for up to 4 cycles in Phase 1 portion of the study and are evaluable.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
55
Approved, Date: 6 October 2015  
The estimated numbers of subjects are 15 (20 if the interim dose is tested) for Phase 1, and 17
for Phase 2 (including those who received the MTD of cytarabine in Phase 1) allowing for 
those who are not evaluable.
11.3.
Phase 1 Analysis
Subjects in the Phase 1 portion will be assessed for toxicity (DLT) to determine the 
recommended dose of cytarabine for the Phase 2 study.
11.4.
Efficacy Analyses 
Criteria
Primary Endpoint
The primary efficacy endpoint is the response rate of CR + CRi for evaluable subjects from 
the Phase 2 part of the study. The best response observed at any time point during the first 
4 cycles of study treatment will be used.
Best response of CR + CRi for subjects from the Phase 1 part of the study, and from Phase 1 
and Phase 2 parts combined will also be summarized.
The aim of the statistical analysis of the initial efficacy data is to assist decision making for 
further clinical development of DACOGEN sequential therapy. Such a decision will be in 
consultation with regulatory authorities, and will depend primarily on the totality of the data 
from this and other studies, available treatment options for pediatric AML patients at the 
time, and interest of co-operative study groups.
The sequential therapy is considered not to have a clinically interesting activity if the 
underlying response rate (CR + CRi) is 20%, and is considered to have a clinically 
interesting activity if the underlying response rate is 35%. Because of the small sample size 
(15 subjects), only descriptive statistics, ie, the observed response rate of CR + CRi and the 
95% confidence interval (CI), will be provided without any hypothesis testing. Also, due to 
the small sample size, the observed response rate will have much variability. With these 
considerations, descriptive statistical analyses will focus on 2 assessments that are considered 
adequate and reasonable in the context of small sample sizes.
The first analysis is to use the lower boundary of the 95% CI to assess if an underlying 
response rate that is much smaller than 20% can be ruled out. For instance (Table 5), with a 
total of 15 subjects, to rule out an underlying response rate of 5%, there should be at least 
4 responders, and to rule out an underlying response rate of 3%, there should be at least 
3 responders.
The second statistical assessment to assist in decision making is the “false positive” and 
“false negative” error rates. This assessment estimates the probability of chance findings with 
the given sample size. Suppose a “yes” or “no” answer is sought in terms of whether the 
outcome, say x CR + CRi responders out of the 15 subjects, favors a continuation of the 
clinical program. The “false positive” error rate for a “yes” answer is the probability of 
observing x responders when the underlying response rate is 20%; and the “false negative” 
error for a “no” answer is the probability of observing x responders when the underlying 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
56
Approved, Date: 6 October 2015  
response rate is 35%. Table 5 illustrates the false positive and false negative error rates 
depending on the number of responders. For instance, if only 2 or 3 subjects have responded, 
the “false positive” error rate for a “yes” answer is very high (83% or 60%) indicating a “yes” 
is likely an incorrect answer, while the “false negative” error rate for a “no” answer is low 
(6% or 17%) indicating a “no” is likely a correct answer.
Table 5:
Statistical Assessments of Response of CR + CRi (N=15)
Number of
Responders
Response
Rate (%)
Exact
95% CI (%)a
False Positive
Error (%)b
False Negative
Error (%)c
1
6.7
(0.2, 31.9)
96.5
1.4
2
13.3
(1.7, 40.5)
83.3
6.2
3
20.0
(4.3, 48.1)
60.2
17.3
4
26.7
(7.8, 55.1)
35.2
35.2
5
33.3
(11.8, 61.6)
16.4
56.4
6
40.0
(16.3, 67.7)
  6.1
75.5
7
46.7
(21.3, 73.4)
  1.8
88.7
a
Based on Clopper-Pearson Exact Interval
b
Probability of observing this or greater number of responders if the underlying response rate is 20%.
c
Probability of observing this or fewer number of responders if the underlying response rate is 35%.
Major Secondary Endpoints
Duration of CR + CRi, overall response (CR + CRi + PR) rate, event-free survival, and 
overall survival will be summarized. These summaries are also based on data of the Phase 2 
part of the study. Where appropriate, these summaries will be performed on data from the 
Phase 1 part of the study and Phase 1 and Phase 2 parts combined. The start time for EFS and 
OS determination is the date of the first dose of study drug.
11.5.
Pharmacokinetic Analyses 
Population PK analysis of plasma concentration-time data of decitabine will be performed 
using nonlinear mixed-effects modeling. Data may be combined with those of other selected 
studies to support a relevant structural model. Available baseline subject characteristics 
(demographics, laboratory variables, genotypes, race, etc.) will be tested as potential 
covariates affecting PK parameters. Details will be given in a population PK analysis plan 
and the results of the population PK analysis will be presented in a separate report.
A snapshot date for PK samples to be analyzed will be defined, if required. Samples collected 
before this date will be analyzed for decitabine and included in the population PK analysis. 
Samples collected after the snapshot date will be analyzed at a later date, and may be 
included in a population PK re-analysis when they become available after database lock.
Data will be listed for all subjects with available plasma concentrations per treatment group. 
Subjects will be excluded from the PK analysis if their data do not allow for accurate 
assessment of the PK (eg, incomplete administration of the study drug; missing information 
of dosing and sampling times; concentration data not sufficient for PK parameter 
calculation).
All concentrations below the lowest quantifiable concentration or missing data will be labeled 
as such in the concentration database. All subjects and samples excluded from the analysis 
will be clearly documented in the study report.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
57
Approved, Date: 6 October 2015  
For each treatment group, descriptive statistics, including arithmetic mean, SD, coefficient of 
variation, median, minimum, and maximum will be calculated for all individual derived PK 
parameters including exposure information of decitabine.
All plasma concentrations below the lowest quantifiable concentration or missing data will be 
labeled as such in the concentration data presentations or SAS dataset. Concentrations below 
the lower quantifiable concentration will be treated as zero in the summary statistics. All 
subjects and samples excluded from the analysis will be clearly documented in the Clinical 
Study Report.
Descriptive statistics will be used to summarize decitabine serum concentrations at each 
sampling time point and PK parameters of decitabine: Cmin and Cmax. Other PK parameters, 
including but not limited to AUC(t1-t2), t1/2, CL, and V, when available, will also be 
summarized.
11.6.
Pharmacokinetic/Pharmacodynamic Analyses 
The relationship between decitabine plasma concentrations and/or metrics of systemic 
exposure (Cmax, AUC) with markers of pharmacological activities (DNA methylation status, 
gene expression profiles) will be explored using suitable structural models and non-linear 
mixed effect regression techniques.
11.7.
Biomarker Analyses 
Biomarker analyses will be performed and stratified by clinical covariates or molecular 
subgroups using appropriate statistical methods. When too few data are available for 
statistical analyses, data will be summarized with descriptive statistics and/or visualized. 
Pharmacodynamic biomarker results from Phase 1 and 2 will be summarized with descriptive 
statistics and/or visualized for each dose level. Changes in the values of individual 
biomarkers from baseline to selected time points will be summarized by dose cohort.
Correlation of baseline values or changes in biomarker values with response or time-to-event 
endpoints will identify responsive (or resistant) subgroups of patients as well as genes and 
pathways affected by DACOGEN treatment. 
Planned biomarker analyses are dependent upon the availability of appropriate biomarker 
assays and may be deferred if emerging study data show no likelihood of providing useful 
scientific information.
Results of biomarker analyses will be presented in a separate report.
11.8.
Safety Analyses
If appropriate, safety data will be summarized for the Phase 1 part and Phase 2 part of the 
study separately, and for all the 2 parts combined.
Adverse Events
The verbatim terms used in the eCRF by investigators to identify adverse events will be 
coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 15.1 or 
higher. 
All 
reported 
adverse 
events 
with 
onset 
during 
the 
treatment 
phase 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
58
Approved, Date: 6 October 2015  
(ie, treatment-emergent adverse events, and adverse events that have worsened since 
baseline) will be included in the analysis. For each adverse event, the percentage of subjects 
who experience at least 1 occurrence of the given event will be summarized by treatment 
group.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue treatment due to an adverse event, or who experience a 
severe or a serious adverse event.
Clinical Laboratory Tests
Laboratory data will be summarized by type of laboratory test. Reference ranges and 
markedly abnormal results (specified in the Statistical Analysis Plan) will be used in the 
summary of laboratory data. Descriptive statistics will be calculated for each laboratory 
analyte at baseline and at each scheduled time point. Changes from baseline results will be 
presented in pre- versus posttreatment cross-tabulations (with classes for below, within, and 
above normal ranges). A listing of subjects with any laboratory results outside the reference 
ranges will be provided. A listing of subjects with any markedly abnormal laboratory results 
will also be provided.
Parameters with predefined National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) toxicity grades will be summarized. Change from baseline to 
the worst adverse event grade experienced by the subject during the study will be provided as 
shift tables.
Cardiac Monitoring
An assessment of shortening fraction and/or left ventricular ejection fraction (LVEF) will be 
assessed during screening by echocardiogram.
LVEF = left ventricular (LV) diastolic volume – LV systolic volume
LV systolic volume
Shortening Fraction = LV end diastolic diameter – LV end systolic diameter
LV end diastolic diameter
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, and blood pressure (systolic and 
diastolic) values and changes from baseline will be summarized at each scheduled time point. 
The percentage of subjects with values beyond clinically important limits will be 
summarized.
Descriptive statistics will be calculated at baseline and for observed values and changes from 
baseline at each scheduled time point. Frequency tabulations of the abnormalities will be 
made.
Physical Examination
Physical examination findings will be summarized at each scheduled time point. Descriptive 
statistics will be calculated at baseline and for observed values and changes from baseline at 
each scheduled time point. Frequency tabulations of the abnormalities will be made.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
59
Approved, Date: 6 October 2015  
11.9.
Study Evaluation Team
A Study Evaluation Team (SET) will be established to review the safety data of the Phase 1 
portion of the study to determine dose escalation, dose de-escalation, and the MTD of 
cytarabine. 
The SET consists of the sponsor’s statistician and clinician (one of whom will chair the 
committee) and other members as needed, eg, clinical pharmacologist, safety physician. The 
SET will also include the lead investigator or designee from each country where the study is 
being conducted. The SET will convene regularly during the Phase 1 portion of this study to 
assess DLTs, determine dose escalation or de-escalation, and whether a MTD has been 
reached for cytarabine under these study conditions. The SET may convene at additional 
times for data review or any safety-related issues including during Phase 2. Any SET member 
has the right to request a SET meeting. A medical consultant may be asked to participate in 
the SET if deemed necessary in the interest of patient safety, upon request from the Sponsor 
or the investigator in preparation for SET meetings. Decisions on dose escalations or 
de-escalations, changes in the timing of PK or PD sampling, or other study conduct 
recommendations, will be made by the SET and documented. 
All decisions made by the SET (eg, dose escalation/de-escalation, modification of the 
administration schedule or regimen) will be documented in a SET decision document and 
distributed to investigators. The IRB will be notified before implementation of any SET 
decision, if required. This document template will be provided in the sponsor’s instruction 
manual and retained in the study master file and in the study center’s files.
12.
ADVERSE EVENT REPORTING
Timely, accurate, and complete reporting and analysis of safety information from clinical 
studies are crucial for the protection of subjects, investigators, and the sponsor, and are 
mandated by regulatory agencies worldwide. The sponsor has established Standard Operating 
Procedures in conformity with regulatory requirements worldwide to ensure appropriate 
reporting of safety information; all clinical studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
12.1.
Definitions
12.1.1.
Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study subject administered 
a medicinal (investigational or non-investigational) product. An adverse event does not 
necessarily have a causal relationship with the treatment. An adverse event can therefore be 
any unfavorable and unintended sign (including an abnormal finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational or non-investigational) 
product, whether or not related to that medicinal (investigational or non-investigational) 
product. (Definition per International Conference on Harmonisation [ICH])
This includes any occurrence that is new in onset or aggravated in severity or frequency from 
the baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
60
Approved, Date: 6 October 2015  
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.2.1, All Adverse Events, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

Results in death

Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Is a congenital anomaly/birth defect

Is a suspected transmission of any infectious agent via a medicinal product

Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is also appropriate in other situations, such as important medical events that may 
not be immediately life threatening or result in death or hospitalization but may jeopardize 
the subject or may require intervention to prevent one of the other outcomes listed in the 
definition above. These should usually be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a 
causal relationship between the study drug and the event (eg, death from anaphylaxis), the 
event must be reported as a serious and unexpected suspected adverse reaction even if it is a 
component of the study endpoint (eg, all-cause mortality).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity is not consistent with the 
applicable product reference safety information. For DACOGEN, the expectedness of an 
adverse event will be determined by whether or not it is listed in the Investigator's Brochure. 
For cytarabine, with a marketing authorization, the expectedness of an adverse event will be 
determined by whether or not it is listed in the SmPC.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is 
possible, probable, or very likely by the definitions listed in Section 12.1.2.
12.1.2.
Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
61
Approved, Date: 6 October 2015  
Doubtful
An adverse event for which an alternative explanation is more likely, eg, concomitant 
drug(s), concomitant disease(s), or the relationship in time suggests that a causal relationship 
is unlikely.
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg, concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is 
suggestive (eg, confirmed by dechallenge). An alternative explanation is less likely, 
eg, concomitant drug(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonably 
explained by an alternative explanation, eg, concomitant drug(s), concomitant disease(s). The 
relationship in time is very suggestive (eg, it is confirmed by dechallenge and rechallenge).
12.1.3.
Severity Criteria 
An assessment of severity grade will be made using the National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. Special Reporting 
Situations
Safety events of interest on a sponsor study drug that may require expedited reporting and/or 
safety evaluation include, but are not limited to:

Overdose of a sponsor study drug

Suspected abuse/misuse of a sponsor study drug

Inadvertent or accidental exposure to a sponsor study drug

Any failure of expected pharmacologic action (ie, lack of effect) of a sponsor study drug

Unexpected therapeutic or clinical benefit from use of a sponsor study drug

Medication error involving a sponsor product (with or without subject/patient exposure 
to the sponsor study drug, eg, name confusion)
Special reporting situations should be recorded in the eCRF. Any special reporting situation 
that meets the criteria of a serious adverse event should be recorded on the serious adverse 
event page of the eCRF.
12.2.
Procedures
12.2.1.
All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICF is obtained until 30 days after the last dose of 
study drug. Serious adverse events, including those spontaneously reported to the investigator 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
62
Approved, Date: 6 October 2015  
within 30 days after the last dose of study drug, must be reported using the Serious Adverse 
Event Form. The sponsor will evaluate any safety information that is spontaneously reported 
by an investigator beyond the time frame specified in the protocol.
All events that meet the definition of a serious adverse event will be reported as serious 
adverse events, regardless of whether they are protocol-specific assessments.
All adverse events, regardless of seriousness, severity, or presumed relationship to study 
drug, must be recorded using medical terminology in the source document and the eCRF. 
Whenever possible, diagnoses should be given when signs and symptoms are due to a 
common etiology (eg, cough, runny nose, sneezing, sore throat, and head congestion should 
be reported as "upper respiratory infection"). Investigators must record in the eCRF their 
opinion concerning the relationship of the adverse event to study therapy. All measures 
required for adverse event management must be recorded in the source document and 
reported according to sponsor instructions.
The sponsor assumes responsibility for appropriate reporting of adverse events to the 
regulatory authorities. The sponsor will also report to the investigator (and the head of the 
investigational institute where required) all serious adverse events that are unlisted 
(unexpected) and associated with the use of the study drug. The investigator (or sponsor 
where required) must report these events to the appropriate Independent Ethics 
Committee/Institutional Review Board (IEC/IRB) that approved the protocol unless 
otherwise required and documented by the IEC/IRB. 
An adverse event is any untoward medical occurrence in a clinical study subject administered 
a medicinal (investigational or non-investigational) product. An adverse event does not 
necessarily have a causal relationship with the treatment. An adverse event can therefore be 
any unfavorable and unintended sign (including an abnormal finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational or non-investigational) 
product, whether or not related to that medicinal (investigational or non-investigational) 
product. (Definition per International Conference on Harmonisation [ICH])
This includes any occurrence that is new in onset or aggravated in severity or frequency from 
the baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.2.1, All Adverse Events, for time of last adverse event recording).
12.2.2.
Serious Adverse Events
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for 
Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

Results in death

Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)

Requires inpatient hospitalization or prolongation of existing hospitalization
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
63
Approved, Date: 6 October 2015  

Results in persistent or significant disability/incapacity

Is a congenital anomaly/birth defect

Is a suspected transmission of any infectious agent via a medicinal product

Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is also appropriate in other situations, such as important medical events that may 
not be immediately life threatening or result in death or hospitalization but may jeopardize 
the subject or may require intervention to prevent one of the other outcomes listed in the 
definition above. These should usually be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a 
causal relationship between the study drugs and the event (eg, death from anaphylaxis), then 
the event must be reported as a serious and unexpected suspected adverse reaction even if it is 
a component of the study endpoint (eg, all-cause mortality). 
All serious adverse events occurring during the study must be reported to the appropriate 
sponsor contact person by study-site personnel within 24 hours of their knowledge of the 
event.
Information regarding serious adverse events will be transmitted to the sponsor using the 
Serious Adverse Event Form, which must be completed and signed by a physician from the 
study site, and transmitted to the sponsor within 24 hours. The initial and follow-up reports of 
a serious adverse event should be made by facsimile (fax).
All serious adverse events that have not resolved by the end of the study, or that have not 
resolved upon discontinuation of the subject's participation in the study, must be followed 
until any of the following occurs:

The event resolves

The event stabilizes

The event returns to baseline, if a baseline value/status is available

The event can be attributed to agents other than the study drug or to factors unrelated to 
study conduct

It becomes unlikely that any additional information can be obtained (subject or health 
care practitioner refusal to provide additional information, lost to follow-up after 
demonstration of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a study must be reported as a 
serious adverse event, except hospitalizations for the following:

Administration of study drugs

Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long-term care facility)
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
64
Approved, Date: 6 October 2015  

Surgery or procedure planned before entry into the study (must be documented in the 
eCRF). Note: Hospitalizations that were planned before the signing of the ICF, and 
where the underlying condition for which the hospitalization was planned has not 
worsened, will not be considered serious adverse events. Any adverse event that results 
in a prolongation of the originally planned hospitalization is to be reported as a new 
serious adverse event.

For convenience the investigator may choose to hospitalize the subject for the duration of 
the treatment period.
12.2.3.
Disease Progression
Disease progression should not be recorded as an adverse event or serious adverse event 
term; instead, signs and symptoms of clinical sequelae resulting from disease 
progression/lack of efficacy will be reported if they fulfill the serious adverse event definition 
(refer to Section 12.1.1, Adverse Event Definitions and Classifications).
12.2.4.
Pregnancy 
All initial reports of pregnancy must be reported to the sponsor by the study-site personnel
within 24 hours of their knowledge of the event using the appropriate pregnancy notification 
form. Abnormal pregnancy outcomes (eg, spontaneous abortion, stillbirth, and congenital 
anomaly) are considered serious adverse events and must be reported using the Serious 
Adverse Event Form. Any subject who becomes pregnant during the study must be promptly 
withdrawn from the study and discontinue further study treatment. 
Because the study drug may have an effect on sperm, pregnancies in partners of male subjects 
included in the study will be reported by the study-site personnel within 24 hours of their 
knowledge of the event, using the appropriate pregnancy notification form.
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in 
the infant will be required.
12.3.
Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be
contacted regarding safety issues or questions regarding the study are listed on the Contact 
Information page(s), which will be provided as a separate document.
13.
PRODUCT QUALITY COMPLAINT HANDLING
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may 
have an impact on the safety and efficacy of the product. Timely, accurate, and complete 
reporting and analysis of PQC information from studies are crucial for the protection of 
subjects, investigators, and the sponsor, and are mandated by regulatory agencies worldwide. 
The sponsor has established procedures in conformity with regulatory requirements 
worldwide to ensure appropriate reporting of PQC information; all studies conducted by the 
sponsor or its affiliates will be conducted in accordance with those procedures.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
65
Approved, Date: 6 October 2015  
13.1.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours 
after being made aware of the event.
If the defect is combined with a serious adverse event, the study-site personnel must report 
the PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 12.2.2, Serious Adverse Events). A sample of the suspected product should be 
maintained for further investigation if requested by the sponsor.
13.2.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be 
contacted regarding product quality issues are listed on the Contact Information page(s), 
which will be provided as a separate document.
14.
STUDY DRUG INFORMATION
14.1.
Physical Description of Study Drug(s)
The DACOGEN supplied for this study is the commercially approved product that will be 
relabeled in local languages as “Clinical Supply Only”. DACOGEN (decitabine) for Injection 
is a white to almost white sterile lyophilized powder supplied in a single-use 20 ml vial 
containing 50 mg decitabine. It will be manufactured and provided under the responsibility of 
the sponsor. Refer to the Investigator's Brochure for a list of excipients.
Cytarabine for this study will be the commercially approved product and locally sourced by 
each investigator site. Refer to the SmPC of cytarabine for product details.
14.2.
Packaging
DACOGEN will be packaged in individual subject kits. Each kit will consist of 5 20 mL vials 
containing 50 mgs of lyophilized decitabine.
14.3.
Labeling
Study drug labels will contain information to meet the applicable regulatory requirements.
14.4.
Preparation, Handling, and Storage 
All study drug must be stored according to the clinical trial label.
Refer to the pharmacy manual/study site Investigational Product instruction Manual or 
equivalent for additional guidance on study drug preparation, handling, and storage.
14.5.
Drug Accountability
The investigator is responsible for ensuring that all study drugs received at the site is 
inventoried and accounted for throughout the study. The study drugs administered to the 
subject must be documented on the drug accountability form. All study drugs will be stored 
and disposed of according to the sponsor's instructions. Study-site personnel must not 
combine contents of the study drug containers.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
66
Approved, Date: 6 October 2015  
Study drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study site in a limited-access area or in a locked cabinet under 
appropriate environmental conditions. Unused study drug must be available for verification 
by the sponsor's study site monitor during on-site monitoring visits. The return to the sponsor 
of unused study drug will be documented on the drug return form. When the study site is an 
authorized destruction unit and study drug supplies are destroyed on-site, this must also be 
documented on the drug return form.
Potentially hazardous materials such as used ampules, needles, syringes, vials, and infusion 
materials containing hazardous liquids, should be disposed of immediately in a safe manner 
and therefore will not be retained for drug accountability purposes. 
Study drug should be dispensed under the supervision of the investigator or a qualified 
member of the study-site personnel, or by a hospital/clinic pharmacist. Study drug will be 
supplied only to subjects participating in the study. Returned study drug must not be 
dispensed again, even to the same subject. Study drug may not be relabeled or reassigned for 
use by other subjects. The investigator agrees neither to dispense the study drug from, nor 
store it at, any site other than the study sites agreed upon with the sponsor.
15.
STUDY-SPECIFIC MATERIALS
The investigator will be provided with the following supplies:

Investigator Brochure for DACOGEN; SmPC for cytarabine

Pharmacy manual/study site investigational product manual

Laboratory manual

NCI-CTCAE Version [4.0]

IVRS/IWRS Manual

eDC Manual

Sample ICF

Lab kits
16.
ETHICAL ASPECTS
16.1.
Study-Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study and, during 
the study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent/assent to participate in the study is voluntary 
and may be withdrawn at any time with no reason given and without penalty or loss of benefits 
to which they would otherwise be entitled. Only subjects who are fully able to understand the 
risks, benefits, and potential adverse events of the study, and provide their consent/assent
voluntarily will be enrolled.
When referring to the signing of the ICF, the terms legal guardian and legally acceptable 
representative refer to the legally appointed guardian of the child with authority to authorize 
participation in research. For each subject, his or her parent(s) (preferably both parents, if 
available) or a legally acceptable representative(s), as required by local regulations, must give 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
67
Approved, Date: 6 October 2015  
written consent/assent (permission) according to local requirements after the nature of the study 
has been fully explained and before the performance of any study-related assessments. Assent 
must be obtained from children (minors) capable of understanding the nature of the study, 
typically subjects 7 years of age and older, depending on the institutional policies. For the 
purposes of this study, all references to subjects who have provided consent/assent (and assent 
as applicable) refers to the subjects and his or her parent(s) or the subject's legal guardian(s) or 
legally acceptable representative(s) who have provided consent/assent according to this 
process. Minors who assent to a study and later withdraw that assent should not be maintained 
in the study against their will, even if their parents still want them to participate.
The total blood volume to be collected is considered to be within the normal range for blood 
collection from pediatric subjects.
16.2.
Regulatory Ethics Compliance
16.2.1.
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory 
and country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and 
well-being of study subjects are protected, consistent with the principles that originated in the 
Declaration of Helsinki, and that the study data are credible.
16.2.2.
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations):

Final protocol and, if applicable, amendments

Sponsor-approved ICF (and any other written materials to be provided to the subjects)

Investigator's Brochure (or equivalent information) and amendments/addenda

Sponsor-approved subject recruiting materials

Information on compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable

Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB)

Information regarding funding, name of the sponsor, institutional affiliations, other 
potential conflicts of interest, and incentives for subjects

Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the ICF, applicable recruiting materials, 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
68
Approved, Date: 6 October 2015  
and subject compensation programs, and the sponsor has received a copy of this approval. 
This approval letter must be dated and must clearly identify the IEC/IRB and the documents 
being approved.
During the study the investigator (or sponsor where required) will send the following 
documents and updates to the IEC/IRB for their review and approval, where appropriate:

Protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct)

Revision(s) to ICF and any other written materials to be provided to subjects

If applicable, new or revised subject recruiting materials approved by the sponsor

Revisions to compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable

New edition(s) of the Investigator's Brochure and amendments/addenda

Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB
(at least annually)

Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study drug

New information that may adversely affect the safety of the subjects or the conduct of 
the study

Deviations from or changes to the protocol to eliminate immediate hazards to the 
subjects

Report of deaths of subjects under the investigator's care

Notification if a new investigator is responsible for the study at the site

Development Safety Update Report and Line Listings, where applicable

Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICF
revisions must be submitted promptly to the IEC/IRB for review and approval before 
implementation of the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study. The 
reapproval should be documented in writing (excluding the ones that are purely 
administrative, with no consequences for subjects, data, or study conduct).
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB 
about the study completion (if applicable, the notification will be submitted through the head 
of investigational institution).
16.2.3.
Informed Consent/assent
Each subject (parent/legal guardian and/or subject as per local regulations) must give written 
consent/assent according to local requirements after the nature of the study has been fully 
explained. The ICF(s) must be signed before performance of any study-related activity. The 
ICF(s) and assent form that is/are used must be approved by both the sponsor and by the 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
69
Approved, Date: 6 October 2015  
reviewing IEC/IRB and be in a language that the subject can read and understand. The 
informed consent/assent should be in accordance with principles that originated in the 
Declaration of
Helsinki, current ICH and GCP guidelines, applicable regulatory 
requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site 
personnel must explain to potential subjects or their legally acceptable representatives the 
aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any 
discomfort participation in the study may entail. Subjects will be informed that their 
participation is voluntary and that they may withdraw consent/assent to participate at any 
time. They will be informed that choosing not to participate will not affect the care the 
subject will receive for the treatment of his or her disease. Subjects will be told that 
alternative treatments are available if they refuse to take part and that such refusal will not
prejudice future treatment. Finally, they will be told that the investigator will maintain a 
subject identification register for the purposes of long-term follow up if needed and that their 
records may be accessed by health authorities and authorized sponsor personnel without 
violating the confidentiality of the subject, to the extent permitted by the applicable law(s) or 
regulations. By signing the ICF the subject or legally acceptable representative is authorizing 
such access, including permission to obtain information about his or her survival status, and 
agrees to allow his or her study physician to recontact the subject for the purpose of obtaining 
consent/assent for additional safety evaluations, if needed, and subsequent disease-related 
treatments, or to obtain information about his or her survival status.
The subject or legally acceptable representative will be given sufficient time to read the ICF 
and the opportunity to ask questions. After this explanation and before entry into the study, 
consent/assent should be appropriately recorded by means of either the subject's or his or her 
legally acceptable representative's personally dated signature. After having obtained the 
consent/assent, a copy of the ICF must be given to the subject.
If the subject or legally acceptable representative is unable to read or write, an impartial 
witness should be present for the entire informed consent/assent process (which includes 
reading and explaining all written information) and should personally date and sign the ICF
after the oral consent/assent of the subject or legally acceptable representative is obtained.
Children (minors) or subjects who are unable to comprehend the information provided can be 
enrolled only after obtaining consent/assent of a legally acceptable representative. Assent 
must be obtained from children (minors) capable of understanding the nature of the study, 
typically subjects 7 years of age and older, depending on the institutional policies. Written 
assent should be obtained from subjects who are able to write. A separate assent form written 
in language the subject can understand should be developed for adolescents. After having 
obtained the assent, a copy of the assent form must be given to the subject, and to the 
subject's parent and/or legally acceptable representative.
When prior consent/assent of the subject is not possible and the subject's legally acceptable 
representative is not available, enrollment procedures should be described in the protocol 
with documented approval/favorable opinion by the IEC/IRB to protect the rights, safety, and 
well-being of the subject and to ensure compliance with applicable regulatory requirements. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
70
Approved, Date: 6 October 2015  
The subject or legally acceptable representative must be informed about the study as soon as 
possible and give consent/assent to continue.
16.2.4.
Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure 
confidentiality and compliance with applicable data privacy protection laws and regulations. 
Appropriate technical and organizational measures to protect the personal data against 
unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor personnel whose responsibilities require access to 
personal data agree to keep the identity of subjects confidential.
The informed consent/assent obtained from the subject (or his or her legally acceptable 
representative) includes explicit consent/assent for the processing of personal data and for the 
investigator/institution to allow direct access to his or her original medical records (source 
data/documents) for study-related monitoring, audit, IEC/IRB review, and regulatory 
inspection. This consent/assent also addresses the transfer of the data to other entities and to 
other countries.
The subject has the right to request through the investigator access to his or her personal data 
and the right to request rectification of any data that are not correct or complete. Reasonable 
steps will be taken to respond to such a request, taking into consideration the nature of the 
request, the conditions of the study, and the applicable laws and regulations.
Exploratory pharmacodynamic, biomarker, and PK research is not conducted under standards 
appropriate for the return of data to subjects. In addition, the sponsor cannot make decisions 
as to the significance of any findings resulting from exploratory research. Therefore, 
exploratory research data will not be returned to subjects or investigators, unless required by 
law or local regulations. Privacy and confidentiality of data generated in the future on stored 
samples will be protected by the same standards applicable to all other clinical data.
16.2.5.
Country Selection
This study will only be conducted in those countries where the intent is to launch or 
otherwise help ensure access to the developed product, unless explicitly addressed as a 
specific ethical consideration in Section 16.1, Study-Specific Design Considerations.
17.
ADMINISTRATIVE REQUIREMENTS
17.1.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal 
amendment by the sponsor. All protocol amendments must be issued by the sponsor, and 
signed and dated by the investigator. Protocol amendments must not be implemented without 
prior IEC/IRB approval, or when the relevant competent authority has raised any grounds for 
non-acceptance, except when necessary to eliminate immediate hazards to the subjects, in 
which case the amendment must be promptly submitted to the IEC/IRB and relevant 
competent authority. Documentation of amendment approval by the investigator and 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
71
Approved, Date: 6 October 2015  
IEC/IRB must be provided to the sponsor. When the change(s) involves only logistic or 
administrative aspects of the study, the IRB (and IEC where required) only needs to be 
notified.
During the course of the study, in situations where a departure from the protocol is 
unavoidable, the investigator or other physician in attendance will contact the appropriate 
sponsor representative (see Contact Information page(s) provided separately). Except in 
emergency situations, this contact should be made before implementing any departure from 
the protocol. In all cases, contact with the sponsor must be made as soon as possible to 
discuss the situation and agree on an appropriate course of action. The data recorded in the 
eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2.
Regulatory Documentation
17.2.1.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory 
authorities in each respective country, if applicable. A study may not be initiated until all 
local regulatory requirements are met.
17.2.2.
Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study drug to 
the study site:

Protocol and amendment(s), if any, signed and dated by the principal investigator

A copy of the dated and signed (or sealed, where appropriate per local regulations), 
written IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, 
and if applicable, subject compensation programs. This approval must clearly identify 
the specific protocol by title and number and must be signed (or sealed, where 
appropriate per local regulations) by the chairman or authorized designee.

Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and 
the applicable laws and regulations. If accompanied by a letter of explanation, or 
equivalent, from the IEC/IRB, a general statement may be substituted for this list. If an 
investigator or a member of the study-site personnel is a member of the IEC/IRB, 
documentation must be obtained to state that this person did not participate in the 
deliberations or in the vote/opinion of the study.

Regulatory authority approval or notification, if applicable

Signed and dated statement of investigator (eg, Form FDA 1572), if applicable

Documentation of investigator qualifications (eg, curriculum vitae)

Completed investigator financial disclosure form from the principal investigator, where 
required

Signed and dated clinical trial agreement, which includes the financial agreement

Any other documentation required by local regulations
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
72
Approved, Date: 6 October 2015  
The following documents must be provided to the sponsor before enrollment of the first 
subject:

Completed investigator financial disclosure forms from all subinvestigators

Documentation of subinvestigator qualifications (eg, curriculum vitae)

Name and address of any local laboratory conducting tests for the study, and a dated 
copy of current laboratory normal ranges for these tests, if applicable

Local laboratory documentation demonstrating competence and test reliability 
(eg, accreditation/license), if applicable
17.3.
Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study. This document will be reviewed by 
the sponsor study-site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed 
by the investigator in the study file. To ensure subject confidentiality, no copy will be made. 
All reports and communications relating to the study will identify subjects by subject 
identification and date of birth. In cases where the subject is not randomized into the study, 
the date seen and date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects 
who were seen to determine eligibility for inclusion in the study.
17.4.
Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility, and study identification; study 
discussion and date of signed informed consent/assent; dates of visits; results of safety and 
efficacy parameters as required by the protocol; record of all adverse events and follow-up of 
adverse events; concomitant medication; drug receipt/dispensing/return records; study drug
administration information; and date of study completion and reason for early discontinuation 
of study drug or withdrawal from the study, if applicable. 
In addition, the author of an entry in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly recorded at the study site as a basis for standard medical care. 
Specific details required as source data for the study will be reviewed with the investigator 
before the study and will be described in the monitoring guidelines (or other equivalent 
document).
The following data will be recorded directly into the CRF and will be considered source data: 

Race

Blood pressure and pulse/heart rate 

Height and weight 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
73
Approved, Date: 6 October 2015  
The minimum source documentation requirements for Section 4.1, Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify a need for documented medical history are as 
follows:

Referral letter from treating physician or

Complete history of medical notes at the site

Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at 
a minimum by subject interview or other protocol required assessment (eg, physical 
examination, laboratory assessment) and documented in the source documents.
17.5.
Case Report Form Completion
Case report forms are provided for each subject in electronic format. 
Electronic Data Capture (eDC) will be used for this study. The study data will be transcribed 
by study-site personnel from the source documents onto an electronic CRF (eCRF), and 
transmitted in a secure manner to the sponsor within the timeframe agreed upon between the 
sponsor and the study site. The electronic file will be considered to be the CRF.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. 
Any such worksheets will become part of the subject's source documentation. All data 
relating to the study must be recorded in CRFs prepared by the sponsor. Data must be entered 
into CRFs in English. Study site personnel must complete the CRF as soon as possible after a 
subject visit, and the forms should be available for review at the next scheduled monitoring 
visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by the same individual who made the initial baseline determinations whenever 
possible. The investigator must verify that all data entries in the CRFs are accurate and 
correct.
All CRF entries, corrections, and alterations must be made by the investigator or other 
authorized study-site personnel. If necessary, queries will be generated in the eDC tool. The 
investigator or study-site personnel must adjust the CRF (if applicable) and complete the 
query. 
If corrections to a CRF are needed after the initial entry into the eCRF, this can be done in 3 
different ways:

Study site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated by the eDC tool).

Study site manager can generate a query for resolution by the study-site personnel.

Clinical data manager can generate a query for resolution by the study-site personnel.
17.6.
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of 
qualified investigators and appropriate study sites, review of protocol procedures with the 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
74
Approved, Date: 6 October 2015  
investigator and study-site personnel before the study, and periodic monitoring visits by the 
sponsor. Written instructions will be provided for collection, handling, storage, and shipment 
of samples. 
Guidelines for CRF completion will be provided and reviewed with study-site personnel 
before the start of the study. The sponsor will review CRFs for accuracy and completeness 
during on-site monitoring visits and after transmission to the sponsor; any discrepancies will 
be resolved with the investigator or designee, as appropriate. After upload of the data into the 
study database they will be verified for accuracy and consistency with the data sources. 
17.7.
Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all 
CRFs and all source documents that support the data collected from each subject, as well as 
all study documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct 
of a Clinical Trial, and all study documents as specified by the applicable regulatory 
requirement(s). The investigator/institution will take measures to prevent accidental or 
premature destruction of these documents.
Essential documents must be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will 
be retained for a longer period if required by the applicable regulatory requirements or by an 
agreement with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. The sponsor must be notified in writing of the name and address of
the new custodian. Under no circumstance shall the investigator relocate or dispose of any 
study documents before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the investigator/institution must permit access to such 
reports.
17.8.
Monitoring
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor 
will record dates of the visits in a study site visit log that will be kept at the study site. The 
first post-initiation visit will be made as soon as possible after enrollment has begun. At these 
visits, the monitor will compare the data entered into the CRFs with the hospital or clinic 
records (source documents). The nature and location of all source documents will be 
identified to ensure that all sources of original data required to complete the CRF are known 
to the sponsor and study-site personnel and are accessible for verification by the sponsor 
study-site contact. If electronic records are maintained at the study site, the method of 
verification must be discussed with the study-site personnel. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
75
Approved, Date: 6 October 2015  
Direct access to source documentation (medical records) must be allowed for the purpose of 
verifying that the data recorded in the CRF are consistent with the original source data. 
Findings from this review of CRFs and source documents will be discussed with the 
study-site personnel. The sponsor expects that, during monitoring visits, the relevant 
study-site personnel will be available, the source documentation will be accessible, and a 
suitable environment will be provided for review of study-related documents. The monitor 
will meet with the investigator on a regular basis during the study to provide feedback on the 
study conduct.
17.9.
Study Completion/Termination
17.9.1.
Study Completion
The study is considered completed with the last study assessment for the last subject 
participating in the study. The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final subject assessment at that study site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2.
Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for 
any reason at the sole discretion of the sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but 
are not limited to:

Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB 
or local health authorities, the sponsor's procedures, or GCP guidelines

Inadequate recruitment of subjects by the investigator

Discontinuation of further study drug development
17.10. On-Site Audits
Representatives of the sponsor's clinical quality assurance department may visit the study site 
at any time during or after completion of the study to conduct an audit of the study in 
compliance with regulatory guidelines and company policy. These audits will require access 
to all study records, including source documents, for inspection and comparison with the 
CRFs. Subject privacy must, however, be respected. The investigator and study-site 
personnel are responsible for being present and available for consultation during routinely 
scheduled study-site audit visits conducted by the sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory body, either 
as part of a national GCP compliance program or to review the results of this study in support 
of a regulatory submission. The investigator should immediately notify the sponsor if they 
have been contacted by a regulatory agency concerning an upcoming inspection.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
76
Approved, Date: 6 October 2015  
17.11. Use of Information and Publication
All information, including but not limited to information regarding DACOGEN or the 
sponsor's operations (eg, patent application, formulas, manufacturing processes, basic 
scientific data, prior clinical data, formulation information) supplied by the sponsor to the 
investigator and not previously published, and any data, including biomarker research data, 
generated as a result of this study, are considered confidential and remain the sole property of 
the sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish this study, and will not use it for other purposes without the 
sponsor's prior written consent/assent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of DACOGEN, and thus may be 
disclosed as required to other clinical investigators or regulatory agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to 
provide the sponsor with all data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by the sponsor 
and will contain CRF data from all study sites that participated in the study. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of 
the study will be used to determine a coordinating investigator. Results of biomarker analyses 
performed after the Clinical Study Report has been issued will be reported in a separate 
report and will not require a revision of the Clinical Study Report. Study subject identifiers 
will not be used in publication of results. Any work created in connection with performance 
of the study and contained in the data that can benefit from copyright protection (except any 
publication by the investigator as provided for below) shall be the property of the sponsor as 
author and owner of copyright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data 
and information without approval from the investigator. The investigator has the right to 
publish study site-specific data after the primary data are published. If an investigator wishes 
to publish information from the study, a copy of the manuscript must be provided to the 
sponsor for review at least 60 days before submission for publication or presentation. 
Expedited reviews will be arranged for abstracts, poster presentations, or other materials. If 
requested by the sponsor in writing, the investigator will withhold such publication for up to 
an additional 60 days to allow for filing of a patent application. In the event that issues arise 
regarding scientific integrity or regulatory compliance, the sponsor will review these issues 
with the investigator. The sponsor will not mandate modifications to scientific content and 
does not have the right to suppress information. For multicenter study designs and substudy 
approaches, secondary results generally should not be published before the primary endpoints 
of a study have been published. Similarly, investigators will recognize the integrity of a 
multicenter study by not submitting for publication data derived from the individual study 
site until the combined results from the completed study have been submitted for publication, 
within 12 months of the availability of the final data (tables, listings, graphs), or the sponsor 
confirms there will be no multicenter study publication. Authorship of publications resulting 
from this study will be based on the guidelines on authorship, such as those described in the 
Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which state that 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
77
Approved, Date: 6 October 2015  
the named authors must have made a significant contribution to the design of the study or 
analysis and interpretation of the data, provided critical review of the paper, and given final 
approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required by law.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
78
Approved, Date: 6 October 2015  
REFERENCES
1.
Atallah E (2007), Garcia-Manero G. Use of hypomethylating agents in myelodysplastic syndromes. Clin 
Advances in Hematology and Oncology 2007;5:544-552.
2.
Attadia V (1993). Effects of 5-aza-2'-deoxycytidine on differentiation and oncogene expression in the 
human monoblastic leukemia cell line U-937. Leukemia 1993;7:9-16.
3.
Bioanalytical Report, LC/MS/MS determination of Decitabine triphosphate (DAC-TP) in various cell line 
samples at various incubation conditions, obtained from study “J&J PRD VI Project, Characterization of 
Ara-C interaction with decitabine. Document ID No.: EDMS-ERI-27389855, Janssen Research and 
Development (19 July 2011). 
4.
Blum W (2007), Klisovic R, Hackanson B, et al. Phase I study of decitabine alone or in combination with 
valproic acid in acute myeloid leukemia. J Clin Oncol 2007;25:3884-3891.
5.
Blum W (2010), Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in 
older AML patients treated with a 10-day schedule of decitabine. PNAS 2010;107:7473-7478.
6.
Cheson BD (2003), Bennett JM, Kopecky KJ, et al. Revised recommendations of the International 
Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting 
standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21:4642-4649.
7.
Clavel J (2004), Goubin A, Auclerc MF, et al. Incidence of childhood leukaemia and non-Hodgkin’s 
lymphoma in France: National Registry of Childhood Leukaemia and Lymphoma, 1990-1999. Eur J 
Cancer Prev 2004;13:97-103.
8.
Clinical Study Report DACO-016 (2011). Randomized Phase 3 Trial of Decitabine Versus Patient’s Choice 
With Physician’s Advice of Either Supportive Care or Low-dose Cytarabine for the Treatment of Older 
Patients With Newly Diagnosed Acute Myeloid Leukemia. Document ID No.: EDMS-ERI-22361193,
Janssen Research and Development (04 Apr 2011).
9.
Clinical Study Report DACO-017 (2008). A Phase II study of decitabine for the front-line treatment of older 
patients with AML. Document ID No.: EDMS-ERI-11100639 Eisai Medical Research, Inc. (22 Dec 2008).
10.
Creitzig U (2012), van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute 
myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 
2012;120:3187-3205.
11.
Investigator’s Brochure: JNJ-30979754 (decitabine), Edition 7. Janssen Research & Development 
(15 Feb 2013).
12.
Drug Safety Evaluation Report TOX9540 (IOW0036): JNJ-30979754: Toxicity study in the neonatal/juvenile 
rat by subcutaneous and intravenous administration. Document ID No.: EDMS-ERI-21429358, Janssen 
Research and Development (08 March 2011).
13.
Epigenomics Report 1: J&J PRD V1 Project Characterization of Ara-C interaction with Decitabine,
Document ID No.: EDMS-ERI-33050622, Epigenomics AG (01 July 2011).
14.
Epigenomics Report 2: J&J PRD V11 Project: Additional experiments for the characterization of Ara-C 
interaction with decitabine. Document ID No.: EDMS-ERI-33105550, Epigenomics AG (26 Oct 2011).
15.
Gore L (2012), Alvaro F, Arndt C, et al. Interim report of a randomized , open-label, multicenter study to 
evaluate the safety and efficacy of decitabine as an epigenetic priming agent when combined with 
induction chemotherapy in pediatric patients with newly diagnosed acute myelogenous leukemia 2012 
ASH annual meeting abstract.
16.
Gorman MF (2010), Ji L, Ko RK, et al. Outcome for Children Treated for Relapsed or Refractory Acute 
Myelogenous Leukemia (rAML): A Therapeutic Advances in Childhood Leukemia (TACL) Consortium 
Study. Pedistr Blood Cancer 2010;55:421-429.
17.
Greaves M (2003). Pre-natal origins of childhood leukemia. Rev Clin Exp Hematol 2003;7:233-245.
18.
Hjalgrim LL (2003), Rostgaard K, Schmiegelow K, et al. Age- and sex-specific incidence of childhood 
leukemia by immunophenotype in the Nordic countries. J Natl Cancer Inst 2003;95:1539-1544.
19.
Inskip PD (1991), Harvey EB, Boice JD Jr, et al. Incidence of childhood cancer in twins. Cancer Causes 
Control 1991;2:315-24.
20.
Issa J-P (2004), Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules 
of the hypomethylating agent 5-aza-2’-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 
2004;103:1635-1640.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
79
Approved, Date: 6 October 2015  
21.
Kantarjian H (2007), Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of 
low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. 
Blood. 2007;109:52-57.
22.
Kantarjian HM (2012), Thomas XG, Dmoszynska A, et al. Multicenter, Randomized, Open-Label, 
Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or 
Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid 
Leukemia. J Clin Oncol 2012;30:2670-2677.
23.
Karnofsky DA (1949), Burchenal JH. "The Clinical Evaluation of Chemotherapeutic Agents in Cancer." 
In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. Columbia Univ Press 1949. Page 196.
24.
Kaspers GJL (2013), Zimmermann M, Reinhardt D, et al. Improved outcome in pediatric relapsed acute 
myeloid leukemia: Results of a randomized trial on liposomal daunorubicin by the international BFM 
Study group. J Clin Oncol 2013:31:599-607.
25.
Kurita S (1974), Kamei Y, Ota K. Genetic studies on familial leukemia. Cancer 1974;34:1098-1101. 
26.
Lansky SB (1987), List MA, Lansky LL, et al. The measurement of performance in childhood cancer 
patients. Cancer 1987;60:1651-1656.
27.
Metzeler KH (2012), Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating 
agent decitabine in acute myeloid leukemia. Leukemia 2012;26:1106-1107.
28.
Miller RW (1967). Persons with exceptionally high risk of leukemia. Cancer Res 1967;27:2420-2423.
29.
Non-clinical Pharmacology Research Report: An analysis of cell growth inhibition, cell cycle analysis and 
apoptosis induction following treatment of primary pediatric AML cultures with decitabine. DNA 
methylation studies and gene expression profiling after defining appropriate dose and timeframe. 
Document ID No.: EDMS-ERI-33054962, Janssen Research and Development (09 Dec 2011).
30.
Non-clinical Pharmacology Research Report: Paediatric AML xenograft models. Document ID 
No.: EDMS-ERI-53399659, Janssen Research and Development (29 Nov 2012).
31.
Periclou AP (1996), Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside 
after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients 
with leukemia. Cancer Chemother Pharmacol 1996;39:42-50.
32.
Pinto A (1984), Attadia V, Fusco A, et al. 5-aza-2’-deoxycytidine induces terminal differentiation of 
leukemic blasts from patients with acute myeloid leukemia. Blood 1984;64:822-829.
33.
Phillips CL (2013), Davies SM, McMasters R, et al. Low dose decitabine in very high risk relapsed or 
refractory acute myeloid leukemia in children and young adults. British J Haematol 2013; doi10.1111/bjh. 
12268.
34.
Population Pharmacokinetic Analysis of Decitabine Injection in Acute Myeloid Leukemia (AML) or 
Myelodysplastic Syndrome (MDS) Patients. Document No.: EDMS-ERI-19812882, Eisai 
Inc.(30 July 2010).
35.
Scandura JM (2011), Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to 
standard induction chemotherapy for patients with AML. Blood 2011;118:1472-1480.
36.
Schag CC (1984), Heinrich RL, Ganz PA. Karnofsky Performance Status Revisited: Reliability, Validity, 
and Guidelines. J Clin Oncol 1984;2:187-193.
37.
Schwartz GJ (1976), Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration 
rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-263.
38.
Shen L (2010), Kantarjian H, Guo Y, et al. DNA Methylation Predicts Survival and Response to Therapy 
in Patients With Myelodysplastic Syndromes. J Clin Oncol. 2010;28:605-613.
39.
Skolnik JM (2008), Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric 
phase I trials: The rolling six design. J Clin Oncol 2008;26:190-195.
40.
Smith MA (1999), Ries LA, Gurney JG, et al. Leukemia. In: Ries LA, Smith MA, Gurney JG, et al., eds.: 
Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. 
Bethesda, MD: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649, p 17-34.
41.
Smith MA (2010), Seibel NL, Altekruse SF, et al. Outcomes for Children and Adolescents With Cancer: 
Challenges for the Twenty-First Century. J Clin Oncol 2010;28:2625-2634.
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
80
Approved, Date: 6 October 2015  
42.
Sposto R (2011), Groshen S. A wide-spectrum paired comparison of the properties of the Rolling 6 and 
3+3 Phase I study designs. Contemporary Clinical Trials 2011;32:694-703. 
43.
Stahnke K (1998), Boos J, Bender-Götze C, et al. Duration of first remission predicts remission rates and 
long-term survival in children with relapsed acute myelogenous leukemia. Leukemia 1998;12:1534-1538.
44.
Summary of Clinical Safety DACOGEN AML Marketing Authorization Application Document ID 
No.: EDMS-ERI-12551254, Janssen Research and Development (12 May 2011).
45.
Vardiman JW, Porwit A, Brunning RD, et al. Introduction and overview of the classification of the 
myeloid neoplasms. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth 
Edition, IARC WHO Classification of Tumours, No 2 Swerdlow ed. IARC 2008.
46.
Webb DK (1999), Wheatley K, Harrison G, et al. Outcome for children with relapsed acute myeloid 
leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC 
Childhood Leukaemia Working Party. Leukemia 1999;13:25-31.
47.
Webb DK (1999). Management of relapsed acute myeloid leukaemia. Br J Haematol 1999;106:851-859.
48.
Wells RJ (2003), Adams MT, Alonzo TA, et al. Mitoxantrone and cytarabine induction, high-dose 
cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid 
leukemia: Children's Cancer Group Study 2951. J Clin Oncol 2003;21:2940-2947. 
49.
Xie Y (2003), Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States 
(1973–1998). Cancer 2003;97:2229–2235.
50.
Zuelzer WW (1969), Cox DE. Genetic aspects of leukemia. Semin Hematol 1969;6:228-49. 
NCT01853228


JNJ-30979754 (decitabine)
Protocol DACOGENAML2004 – Amendment INT-2
81
Approved, Date: 6 October 2015  
INVESTIGATOR AGREEMENT
LAST PAGE
NCT01853228